Medical treatment of viral pneumonia including SARS in immunocompetent adult
Identifieur interne : 001188 ( Pmc/Corpus ); précédent : 001187; suivant : 001189Medical treatment of viral pneumonia including SARS in immunocompetent adult
Auteurs : V. C. C. Cheng ; B. S. F. Tang ; A. K. L. Wu ; C. M. Chu ; K. Y. YuenSource :
- The Journal of Infection [ 0163-4453 ] ; 2004.
Abstract
Since no randomized controlled trials have been conducted on the treatment of viral pneumonia by antivirals or immunomodulators in immunocompetent adults, a review of such anecdotal experience are needed for the more rational use of such agents. Case reports (single or case series) with details on their treatment and outcome in the English literature can be reviewed for pneumonia caused by human or avian influenza A virus (50 patients), varicella zoster virus (120), adenovirus (29), hantavirus (100) and SARS coronavirus (SARS-CoV) (841). Even with steroid therapy alone, the mortality rate appeared to be lower when compared with conservative treatment for pneumonia caused by human influenza virus (12.5% vs. 42.1%) and hantavirus (13.3% vs. 63.4%). Combination of an effective antiviral, acyclovir, with steroid in the treatment of varicella zoster virus may be associated with a lower mortality than acyclovir alone (0% vs. 10.3%). Combination of interferon alfacon-1 plus steroid, or lopinavir/ritonavir, ribavirin plus steroid were associated with a better outcome than ribavirin plus steroid (0% vs. 2.3% vs. 7.7%, respectively). Combination of lopinavir/ritonavir plus ribavirin significantly reduced the virus load of SARS-CoV in nasopharyngeal, serum, stool and urine specimens taken between day 10 and 15 after symptom onset when compared with the historical control group treated with ribavirin. It appears that the combination of an effective antiviral and steroid was associated with a better outcome. Randomized therapeutic trial should be conducted to ascertain the relative usefulness of antiviral alone or in combination with steroid.
Url:
DOI: 10.1016/j.jinf.2004.07.010
PubMed: 15474623
PubMed Central: 7112637
Links to Exploration step
PMC:7112637Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Medical treatment of viral pneumonia including SARS in immunocompetent adult</title><author><name sortKey="Cheng, V C C" sort="Cheng, V C C" uniqKey="Cheng V" first="V. C. C." last="Cheng">V. C. C. Cheng</name><affiliation><nlm:aff id="aff1">Centre of Infection, Queen Mary Hospital, The University of Hong Kong, Hong Kong Special Administrative Region, China</nlm:aff></affiliation></author><author><name sortKey="Tang, B S F" sort="Tang, B S F" uniqKey="Tang B" first="B. S. F." last="Tang">B. S. F. Tang</name><affiliation><nlm:aff id="aff1">Centre of Infection, Queen Mary Hospital, The University of Hong Kong, Hong Kong Special Administrative Region, China</nlm:aff></affiliation></author><author><name sortKey="Wu, A K L" sort="Wu, A K L" uniqKey="Wu A" first="A. K. L." last="Wu">A. K. L. Wu</name><affiliation><nlm:aff id="aff1">Centre of Infection, Queen Mary Hospital, The University of Hong Kong, Hong Kong Special Administrative Region, China</nlm:aff></affiliation></author><author><name sortKey="Chu, C M" sort="Chu, C M" uniqKey="Chu C" first="C. M." last="Chu">C. M. Chu</name><affiliation><nlm:aff id="aff2">Department of Medicine, United Christian Hospital, Hong Kong Special Administrative Region, China</nlm:aff></affiliation></author><author><name sortKey="Yuen, K Y" sort="Yuen, K Y" uniqKey="Yuen K" first="K. Y." last="Yuen">K. Y. Yuen</name><affiliation><nlm:aff id="aff1">Centre of Infection, Queen Mary Hospital, The University of Hong Kong, Hong Kong Special Administrative Region, China</nlm:aff></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">PMC</idno><idno type="pmid">15474623</idno><idno type="pmc">7112637</idno><idno type="url">http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7112637</idno><idno type="RBID">PMC:7112637</idno><idno type="doi">10.1016/j.jinf.2004.07.010</idno><date when="2004">2004</date><idno type="wicri:Area/Pmc/Corpus">001188</idno><idno type="wicri:explorRef" wicri:stream="Pmc" wicri:step="Corpus" wicri:corpus="PMC">001188</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en" level="a" type="main">Medical treatment of viral pneumonia including SARS in immunocompetent adult</title><author><name sortKey="Cheng, V C C" sort="Cheng, V C C" uniqKey="Cheng V" first="V. C. C." last="Cheng">V. C. C. Cheng</name><affiliation><nlm:aff id="aff1">Centre of Infection, Queen Mary Hospital, The University of Hong Kong, Hong Kong Special Administrative Region, China</nlm:aff></affiliation></author><author><name sortKey="Tang, B S F" sort="Tang, B S F" uniqKey="Tang B" first="B. S. F." last="Tang">B. S. F. Tang</name><affiliation><nlm:aff id="aff1">Centre of Infection, Queen Mary Hospital, The University of Hong Kong, Hong Kong Special Administrative Region, China</nlm:aff></affiliation></author><author><name sortKey="Wu, A K L" sort="Wu, A K L" uniqKey="Wu A" first="A. K. L." last="Wu">A. K. L. Wu</name><affiliation><nlm:aff id="aff1">Centre of Infection, Queen Mary Hospital, The University of Hong Kong, Hong Kong Special Administrative Region, China</nlm:aff></affiliation></author><author><name sortKey="Chu, C M" sort="Chu, C M" uniqKey="Chu C" first="C. M." last="Chu">C. M. Chu</name><affiliation><nlm:aff id="aff2">Department of Medicine, United Christian Hospital, Hong Kong Special Administrative Region, China</nlm:aff></affiliation></author><author><name sortKey="Yuen, K Y" sort="Yuen, K Y" uniqKey="Yuen K" first="K. Y." last="Yuen">K. Y. Yuen</name><affiliation><nlm:aff id="aff1">Centre of Infection, Queen Mary Hospital, The University of Hong Kong, Hong Kong Special Administrative Region, China</nlm:aff></affiliation></author></analytic><series><title level="j">The Journal of Infection</title><idno type="ISSN">0163-4453</idno><idno type="eISSN">1532-2742</idno><imprint><date when="2004">2004</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en"><p>Since no randomized controlled trials have been conducted on the treatment of viral pneumonia by antivirals or immunomodulators in immunocompetent adults, a review of such anecdotal experience are needed for the more rational use of such agents. Case reports (single or case series) with details on their treatment and outcome in the English literature can be reviewed for pneumonia caused by human or avian influenza A virus (50 patients), varicella zoster virus (120), adenovirus (29), hantavirus (100) and SARS coronavirus (SARS-CoV) (841). Even with steroid therapy alone, the mortality rate appeared to be lower when compared with conservative treatment for pneumonia caused by human influenza virus (12.5% vs. 42.1%) and hantavirus (13.3% vs. 63.4%). Combination of an effective antiviral, acyclovir, with steroid in the treatment of varicella zoster virus may be associated with a lower mortality than acyclovir alone (0% vs. 10.3%). Combination of interferon alfacon-1 plus steroid, or lopinavir/ritonavir, ribavirin plus steroid were associated with a better outcome than ribavirin plus steroid (0% vs. 2.3% vs. 7.7%, respectively). Combination of lopinavir/ritonavir plus ribavirin significantly reduced the virus load of SARS-CoV in nasopharyngeal, serum, stool and urine specimens taken between day 10 and 15 after symptom onset when compared with the historical control group treated with ribavirin. It appears that the combination of an effective antiviral and steroid was associated with a better outcome. Randomized therapeutic trial should be conducted to ascertain the relative usefulness of antiviral alone or in combination with steroid.</p></div></front><back><div1 type="bibliography"><listBibl><biblStruct><analytic><author><name sortKey="Guan, Y" uniqKey="Guan Y">Y. Guan</name></author><author><name sortKey="Zheng, B J" uniqKey="Zheng B">B.J. Zheng</name></author><author><name sortKey="He, Y Q" uniqKey="He Y">Y.Q. He</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Webster, R G" uniqKey="Webster R">R.G. Webster</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Poutanen, S M" uniqKey="Poutanen S">S.M. Poutanen</name></author><author><name sortKey="Low, D E" uniqKey="Low D">D.E. Low</name></author><author><name sortKey="Henry, B" uniqKey="Henry B">B. Henry</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Tsang, K W" uniqKey="Tsang K">K.W. Tsang</name></author><author><name sortKey="Ho, P L" uniqKey="Ho P">P.L. Ho</name></author><author><name sortKey="Ooi, G C" uniqKey="Ooi G">G.C. Ooi</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Peiris, J S" uniqKey="Peiris J">J.S. Peiris</name></author><author><name sortKey="Lai, S T" uniqKey="Lai S">S.T. Lai</name></author><author><name sortKey="Poon, L L" uniqKey="Poon L">L.L. Poon</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Yuen, K Y" uniqKey="Yuen K">K.Y. Yuen</name></author><author><name sortKey="Chan, P K" uniqKey="Chan P">P.K. Chan</name></author><author><name sortKey="Peiris, M" uniqKey="Peiris M">M. Peiris</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Tran, T H" uniqKey="Tran T">T.H. Tran</name></author><author><name sortKey="Nguyen, T L" uniqKey="Nguyen T">T.L. Nguyen</name></author><author><name sortKey="Nguyen, T D" uniqKey="Nguyen T">T.D. Nguyen</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Peiris, J S" uniqKey="Peiris J">J.S. Peiris</name></author><author><name sortKey="Chu, C M" uniqKey="Chu C">C.M. Chu</name></author><author><name sortKey="Cheng, V C" uniqKey="Cheng V">V.C. Cheng</name></author></analytic></biblStruct><biblStruct></biblStruct><biblStruct><analytic><author><name sortKey="Chu, C M" uniqKey="Chu C">C.M. Chu</name></author><author><name sortKey="Cheng, V C" uniqKey="Cheng V">V.C. Cheng</name></author><author><name sortKey="Hung, I F" uniqKey="Hung I">I.F. Hung</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Cyranoski, D" uniqKey="Cyranoski D">D. Cyranoski</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Knowles, S R" uniqKey="Knowles S">S.R. Knowles</name></author><author><name sortKey="Phillips, E J" uniqKey="Phillips E">E.J. Phillips</name></author><author><name sortKey="Dresser, L" uniqKey="Dresser L">L. Dresser</name></author><author><name sortKey="Matukas, L" uniqKey="Matukas L">L. Matukas</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Oba, Y" uniqKey="Oba Y">Y. Oba</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Bernard, G R" uniqKey="Bernard G">G.R. Bernard</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Chan, K H" uniqKey="Chan K">K.H. Chan</name></author><author><name sortKey="Poon, L L" uniqKey="Poon L">L.L. Poon</name></author><author><name sortKey="Cheng, V C" uniqKey="Cheng V">V.C. Cheng</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Cheng, V C" uniqKey="Cheng V">V.C. Cheng</name></author><author><name sortKey="Hung, I F" uniqKey="Hung I">I.F. Hung</name></author><author><name sortKey="Tang, B S" uniqKey="Tang B">B.S. Tang</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Taylor, G J" uniqKey="Taylor G">G.J. Taylor</name></author><author><name sortKey="Brenner, W" uniqKey="Brenner W">W. Brenner</name></author><author><name sortKey="Summer, W R" uniqKey="Summer W">W.R. Summer</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Winterbauer, R H" uniqKey="Winterbauer R">R.H. Winterbauer</name></author><author><name sortKey="Ludwig, W R" uniqKey="Ludwig W">W.R. Ludwig</name></author><author><name sortKey="Hammar, S P" uniqKey="Hammar S">S.P. Hammar</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Oliveira, E C" uniqKey="Oliveira E">E.C. Oliveira</name></author><author><name sortKey="Marik, P E" uniqKey="Marik P">P.E. Marik</name></author><author><name sortKey="Colice, G" uniqKey="Colice G">G. Colice</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Kawayama, T" uniqKey="Kawayama T">T. Kawayama</name></author><author><name sortKey="Fujiki, R" uniqKey="Fujiki R">R. Fujiki</name></author><author><name sortKey="Rikimaru, T" uniqKey="Rikimaru T">T. Rikimaru</name></author><author><name sortKey="Oizumi, K" uniqKey="Oizumi K">K. Oizumi</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Ferstenfeld, J E" uniqKey="Ferstenfeld J">J.E. Ferstenfeld</name></author><author><name sortKey="Schlueter, D P" uniqKey="Schlueter D">D.P. Schlueter</name></author><author><name sortKey="Rytel, M W" uniqKey="Rytel M">M.W. Rytel</name></author><author><name sortKey="Molloy, R P" uniqKey="Molloy R">R.P. Molloy</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Greaves, I A" uniqKey="Greaves I">I.A. Greaves</name></author><author><name sortKey="Colebatch, H J" uniqKey="Colebatch H">H.J. Colebatch</name></author><author><name sortKey="Torda, T A" uniqKey="Torda T">T.A. Torda</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Doi, M" uniqKey="Doi M">M. Doi</name></author><author><name sortKey="Takao, S" uniqKey="Takao S">S. Takao</name></author><author><name sortKey="Kaneko, K" uniqKey="Kaneko K">K. Kaneko</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Chan, P K" uniqKey="Chan P">P.K. Chan</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Peiris, J S" uniqKey="Peiris J">J.S. Peiris</name></author><author><name sortKey="Yu, W C" uniqKey="Yu W">W.C. Yu</name></author><author><name sortKey="Leung, C W" uniqKey="Leung C">C.W. Leung</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Hockberger, R S" uniqKey="Hockberger R">R.S. Hockberger</name></author><author><name sortKey="Rothstein, R J" uniqKey="Rothstein R">R.J. Rothstein</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Davidson, R N" uniqKey="Davidson R">R.N. Davidson</name></author><author><name sortKey="Lynn, W" uniqKey="Lynn W">W. Lynn</name></author><author><name sortKey="Savage, P" uniqKey="Savage P">P. Savage</name></author><author><name sortKey="Wansbrough Jones, M H" uniqKey="Wansbrough Jones M">M.H. Wansbrough-Jones</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Nilsson, A" uniqKey="Nilsson A">A. Nilsson</name></author><author><name sortKey="Ortqvist, A" uniqKey="Ortqvist A">A. Ortqvist</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Mer, M" uniqKey="Mer M">M. Mer</name></author><author><name sortKey="Richards, G A" uniqKey="Richards G">G.A. Richards</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Laufenburg, H F" uniqKey="Laufenburg H">H.F. Laufenburg</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Oh, H M" uniqKey="Oh H">H.M. Oh</name></author><author><name sortKey="Chew, S K" uniqKey="Chew S">S.K. Chew</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Devaul, K A" uniqKey="Devaul K">K.A. DeVaul</name></author><author><name sortKey="Garner, C E" uniqKey="Garner C">C.E. Garner</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Potgieter, P D" uniqKey="Potgieter P">P.D. Potgieter</name></author><author><name sortKey="Hammond, J M" uniqKey="Hammond J">J.M. Hammond</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Schlossberg, D" uniqKey="Schlossberg D">D. Schlossberg</name></author><author><name sortKey="Littman, M" uniqKey="Littman M">M. Littman</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="El Daher, N" uniqKey="El Daher N">N. El-Daher</name></author><author><name sortKey="Magnussen, R" uniqKey="Magnussen R">R. Magnussen</name></author><author><name sortKey="Betts, R F" uniqKey="Betts R">R.F. Betts</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Chou, D W" uniqKey="Chou D">D.W. Chou</name></author><author><name sortKey="Lee, C H" uniqKey="Lee C">C.H. Lee</name></author><author><name sortKey="Chen, C W" uniqKey="Chen C">C.W. Chen</name></author><author><name sortKey="Chang, H Y" uniqKey="Chang H">H.Y. Chang</name></author><author><name sortKey="Hsiue, T R" uniqKey="Hsiue T">T.R. Hsiue</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Nee, P A" uniqKey="Nee P">P.A. Nee</name></author><author><name sortKey="Edrich, P J" uniqKey="Edrich P">P.J. Edrich</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Hepburn, N C" uniqKey="Hepburn N">N.C. Hepburn</name></author><author><name sortKey="Carley, R H" uniqKey="Carley R">R.H. Carley</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Lau, L G" uniqKey="Lau L">L.G. Lau</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Keane, J" uniqKey="Keane J">J. Keane</name></author><author><name sortKey="Gochuico, B" uniqKey="Gochuico B">B. Gochuico</name></author><author><name sortKey="Kasznica, J M" uniqKey="Kasznica J">J.M. Kasznica</name></author><author><name sortKey="Kornfeld, H" uniqKey="Kornfeld H">H. Kornfeld</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Ahmed, R" uniqKey="Ahmed R">R. Ahmed</name></author><author><name sortKey="Ahmed, Q A" uniqKey="Ahmed Q">Q.A. Ahmed</name></author><author><name sortKey="Adhami, N A" uniqKey="Adhami N">N.A. Adhami</name></author><author><name sortKey="Memish, Z A" uniqKey="Memish Z">Z.A. Memish</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Shirai, T" uniqKey="Shirai T">T. Shirai</name></author><author><name sortKey="Sano, K" uniqKey="Sano K">K. Sano</name></author><author><name sortKey="Matsuyama, S" uniqKey="Matsuyama S">S. Matsuyama</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Tokat, O" uniqKey="Tokat O">O. Tokat</name></author><author><name sortKey="Kelebek, N" uniqKey="Kelebek N">N. Kelebek</name></author><author><name sortKey="Turker, G" uniqKey="Turker G">G. Turker</name></author><author><name sortKey="Kahveci, S F" uniqKey="Kahveci S">S.F. Kahveci</name></author><author><name sortKey="Ozcan, B" uniqKey="Ozcan B">B. Ozcan</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Dudding, B A" uniqKey="Dudding B">B.A. Dudding</name></author><author><name sortKey="Wagner, S C" uniqKey="Wagner S">S.C. Wagner</name></author><author><name sortKey="Zeller, J A" uniqKey="Zeller J">J.A. Zeller</name></author><author><name sortKey="Gmelich, J T" uniqKey="Gmelich J">J.T. Gmelich</name></author><author><name sortKey="French, G R" uniqKey="French G">G.R. French</name></author><author><name sortKey="Top, F H" uniqKey="Top F">F.H. Top</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Pearson, R D" uniqKey="Pearson R">R.D. Pearson</name></author><author><name sortKey="Hall, W J" uniqKey="Hall W">W.J. Hall</name></author><author><name sortKey="Menegus, M A" uniqKey="Menegus M">M.A. Menegus</name></author><author><name sortKey="Douglas, R G" uniqKey="Douglas R">R.G. Douglas</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Retalis, P" uniqKey="Retalis P">P. Retalis</name></author><author><name sortKey="Strange, C" uniqKey="Strange C">C. Strange</name></author><author><name sortKey="Harley, R" uniqKey="Harley R">R. Harley</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Klinger, J R" uniqKey="Klinger J">J.R. Klinger</name></author><author><name sortKey="Sanchez, M P" uniqKey="Sanchez M">M.P. Sanchez</name></author><author><name sortKey="Curtin, L A" uniqKey="Curtin L">L.A. Curtin</name></author><author><name sortKey="Durkin, M" uniqKey="Durkin M">M. Durkin</name></author><author><name sortKey="Matyas, B" uniqKey="Matyas B">B. Matyas</name></author></analytic></biblStruct><biblStruct></biblStruct><biblStruct><analytic><author><name sortKey="Levin, S" uniqKey="Levin S">S. Levin</name></author><author><name sortKey="Dietrich, J" uniqKey="Dietrich J">J. Dietrich</name></author><author><name sortKey="Guillory, J" uniqKey="Guillory J">J. Guillory</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Zarraga, A L" uniqKey="Zarraga A">A.L. Zarraga</name></author><author><name sortKey="Kerns, F T" uniqKey="Kerns F">F.T. Kerns</name></author><author><name sortKey="Kitchen, L W" uniqKey="Kitchen L">L.W. Kitchen</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Levy, H" uniqKey="Levy H">H. Levy</name></author><author><name sortKey="Simpson, S Q" uniqKey="Simpson S">S.Q. Simpson</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Castillo, C" uniqKey="Castillo C">C. Castillo</name></author><author><name sortKey="Naranjo, J" uniqKey="Naranjo J">J. Naranjo</name></author><author><name sortKey="Sepulveda, A" uniqKey="Sepulveda A">A. Sepulveda</name></author><author><name sortKey="Ossa, G" uniqKey="Ossa G">G. Ossa</name></author><author><name sortKey="Levy, H" uniqKey="Levy H">H. Levy</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Riquelme, R" uniqKey="Riquelme R">R. Riquelme</name></author><author><name sortKey="Riquelme, M" uniqKey="Riquelme M">M. Riquelme</name></author><author><name sortKey="Torres, A" uniqKey="Torres A">A. Torres</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Chapman, L E" uniqKey="Chapman L">L.E. Chapman</name></author><author><name sortKey="Ellis, B A" uniqKey="Ellis B">B.A. Ellis</name></author><author><name sortKey="Koster, F T" uniqKey="Koster F">F.T. Koster</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Chapman, L E" uniqKey="Chapman L">L.E. Chapman</name></author><author><name sortKey="Mertz, G J" uniqKey="Mertz G">G.J. Mertz</name></author><author><name sortKey="Peters, C J" uniqKey="Peters C">C.J. Peters</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Aylward, R B" uniqKey="Aylward R">R.B. Aylward</name></author><author><name sortKey="Burdge, D R" uniqKey="Burdge D">D.R. Burdge</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Rupp, M E" uniqKey="Rupp M">M.E. Rupp</name></author><author><name sortKey="Schwartz, M L" uniqKey="Schwartz M">M.L. Schwartz</name></author><author><name sortKey="Bechard, D E" uniqKey="Bechard D">D.E. Bechard</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Haller, A" uniqKey="Haller A">A. Haller</name></author><author><name sortKey="Von Segesser, L" uniqKey="Von Segesser L">L. von Segesser</name></author><author><name sortKey="Baumann, P C" uniqKey="Baumann P">P.C. Baumann</name></author><author><name sortKey="Krause, M" uniqKey="Krause M">M. Krause</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="So, L K" uniqKey="So L">L.K. So</name></author><author><name sortKey="Lau, A C" uniqKey="Lau A">A.C. Lau</name></author><author><name sortKey="Yam, L Y" uniqKey="Yam L">L.Y. Yam</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Choi, K W" uniqKey="Choi K">K.W. Choi</name></author><author><name sortKey="Chau, T N" uniqKey="Chau T">T.N. Chau</name></author><author><name sortKey="Tsang, O" uniqKey="Tsang O">O. Tsang</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Zhao, Z" uniqKey="Zhao Z">Z. Zhao</name></author><author><name sortKey="Zhang, F" uniqKey="Zhang F">F. Zhang</name></author><author><name sortKey="Xu, M" uniqKey="Xu M">M. Xu</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Lee, N" uniqKey="Lee N">N. Lee</name></author><author><name sortKey="Hui, D" uniqKey="Hui D">D. Hui</name></author><author><name sortKey="Wu, A" uniqKey="Wu A">A. Wu</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Ho, J C" uniqKey="Ho J">J.C. Ho</name></author><author><name sortKey="Ooi, G C" uniqKey="Ooi G">G.C. Ooi</name></author><author><name sortKey="Mok, T Y" uniqKey="Mok T">T.Y. Mok</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Chan, K S" uniqKey="Chan K">K.S. Chan</name></author><author><name sortKey="Lai, S T" uniqKey="Lai S">S.T. Lai</name></author><author><name sortKey="Chu, C M" uniqKey="Chu C">C.M. Chu</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Loutfy, M R" uniqKey="Loutfy M">M.R. Loutfy</name></author><author><name sortKey="Blatt, L M" uniqKey="Blatt L">L.M. Blatt</name></author><author><name sortKey="Siminovitch, K A" uniqKey="Siminovitch K">K.A. Siminovitch</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Hsu, L Y" uniqKey="Hsu L">L.Y. Hsu</name></author><author><name sortKey="Lee, C C" uniqKey="Lee C">C.C. Lee</name></author><author><name sortKey="Green, J A" uniqKey="Green J">J.A. Green</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Wong, V W" uniqKey="Wong V">V.W. Wong</name></author><author><name sortKey="Dai, D" uniqKey="Dai D">D. Dai</name></author><author><name sortKey="Wu, A K" uniqKey="Wu A">A.K. Wu</name></author><author><name sortKey="Sung, J J" uniqKey="Sung J">J.J. Sung</name></author></analytic></biblStruct><biblStruct></biblStruct><biblStruct></biblStruct><biblStruct></biblStruct><biblStruct></biblStruct><biblStruct><analytic><author><name sortKey="Booth, C M" uniqKey="Booth C">C.M. Booth</name></author><author><name sortKey="Matukas, L M" uniqKey="Matukas L">L.M. Matukas</name></author><author><name sortKey="Tomlinson, G A" uniqKey="Tomlinson G">G.A. Tomlinson</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Dolin, R" uniqKey="Dolin R">R. Dolin</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Falsey, A R" uniqKey="Falsey A">A.R. Falsey</name></author><author><name sortKey="Formica, M A" uniqKey="Formica M">M.A. Formica</name></author><author><name sortKey="Treanor, J J" uniqKey="Treanor J">J.J. Treanor</name></author><author><name sortKey="Walsh, E E" uniqKey="Walsh E">E.E. Walsh</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="File, T M" uniqKey="File T">T.M. File</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Ruiz Gonzalez, A" uniqKey="Ruiz Gonzalez A">A. Ruiz-Gonzalez</name></author><author><name sortKey="Falguera, M" uniqKey="Falguera M">M. Falguera</name></author><author><name sortKey="Nogues, A" uniqKey="Nogues A">A. Nogues</name></author><author><name sortKey="Rubio Caballero, M" uniqKey="Rubio Caballero M">M. Rubio-Caballero</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Ishida, T" uniqKey="Ishida T">T. Ishida</name></author><author><name sortKey="Hashimoto, T" uniqKey="Hashimoto T">T. Hashimoto</name></author><author><name sortKey="Arita, M" uniqKey="Arita M">M. Arita</name></author><author><name sortKey="Ito, I" uniqKey="Ito I">I. Ito</name></author><author><name sortKey="Osawa, M" uniqKey="Osawa M">M. Osawa</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Robbins, G K" uniqKey="Robbins G">G.K. Robbins</name></author><author><name sortKey="De Gruttola, V" uniqKey="De Gruttola V">V. De Gruttola</name></author><author><name sortKey="Shafer, R W" uniqKey="Shafer R">R.W. Shafer</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Shafer, R W" uniqKey="Shafer R">R.W. Shafer</name></author><author><name sortKey="Smeaton, L M" uniqKey="Smeaton L">L.M. Smeaton</name></author><author><name sortKey="Robbins, G K" uniqKey="Robbins G">G.K. Robbins</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Jaeckel, E" uniqKey="Jaeckel E">E. Jaeckel</name></author><author><name sortKey="Cornberg, M" uniqKey="Cornberg M">M. Cornberg</name></author><author><name sortKey="Wedemeyer, H" uniqKey="Wedemeyer H">H. Wedemeyer</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Fried, M W" uniqKey="Fried M">M.W. Fried</name></author><author><name sortKey="Shiffman, M L" uniqKey="Shiffman M">M.L. Shiffman</name></author><author><name sortKey="Reddy, K R" uniqKey="Reddy K">K.R. Reddy</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Manns, M P" uniqKey="Manns M">M.P. Manns</name></author><author><name sortKey="Mchutchison, J G" uniqKey="Mchutchison J">J.G. McHutchison</name></author><author><name sortKey="Gordon, S C" uniqKey="Gordon S">S.C. Gordon</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Lai, C L" uniqKey="Lai C">C.L. Lai</name></author><author><name sortKey="Chien, R N" uniqKey="Chien R">R.N. Chien</name></author><author><name sortKey="Leung, N W" uniqKey="Leung N">N.W. Leung</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Dienstag, J L" uniqKey="Dienstag J">J.L. Dienstag</name></author><author><name sortKey="Schiff, E R" uniqKey="Schiff E">E.R. Schiff</name></author><author><name sortKey="Wright, T L" uniqKey="Wright T">T.L. Wright</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Leone, P A" uniqKey="Leone P">P.A. Leone</name></author><author><name sortKey="Trottier, S" uniqKey="Trottier S">S. Trottier</name></author><author><name sortKey="Miller, J M" uniqKey="Miller J">J.M. Miller</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Corey, L" uniqKey="Corey L">L. Corey</name></author><author><name sortKey="Wald, A" uniqKey="Wald A">A. Wald</name></author><author><name sortKey="Patel, R" uniqKey="Patel R">R. Patel</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Balfour, H H" uniqKey="Balfour H">H.H. Balfour</name></author><author><name sortKey="Rotbart, H A" uniqKey="Rotbart H">H.A. Rotbart</name></author><author><name sortKey="Feldman, S" uniqKey="Feldman S">S. Feldman</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Wallace, M R" uniqKey="Wallace M">M.R. Wallace</name></author><author><name sortKey="Bowler, W A" uniqKey="Bowler W">W.A. Bowler</name></author><author><name sortKey="Murray, N B" uniqKey="Murray N">N.B. Murray</name></author><author><name sortKey="Brodine, S K" uniqKey="Brodine S">S.K. Brodine</name></author><author><name sortKey="Oldfield, E C" uniqKey="Oldfield E">E.C. Oldfield</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Salmon Ceron, D" uniqKey="Salmon Ceron D">D. Salmon-Ceron</name></author><author><name sortKey="Fillet, A M" uniqKey="Fillet A">A.M. Fillet</name></author><author><name sortKey="Aboulker, J P" uniqKey="Aboulker J">J.P. Aboulker</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Martin, D F" uniqKey="Martin D">D.F. Martin</name></author><author><name sortKey="Sierra Madero, J" uniqKey="Sierra Madero J">J. Sierra-Madero</name></author><author><name sortKey="Walmsley, S" uniqKey="Walmsley S">S. Walmsley</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Nicholson, K G" uniqKey="Nicholson K">K.G. Nicholson</name></author><author><name sortKey="Aoki, F Y" uniqKey="Aoki F">F.Y. Aoki</name></author><author><name sortKey="Osterhaus, A D" uniqKey="Osterhaus A">A.D. Osterhaus</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Treanor, J J" uniqKey="Treanor J">J.J. Treanor</name></author><author><name sortKey="Hayden, F G" uniqKey="Hayden F">F.G. Hayden</name></author><author><name sortKey="Vrooman, P S" uniqKey="Vrooman P">P.S. Vrooman</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Hedrick, J A" uniqKey="Hedrick J">J.A. Hedrick</name></author><author><name sortKey="Barzilai, A" uniqKey="Barzilai A">A. Barzilai</name></author><author><name sortKey="Behre, U" uniqKey="Behre U">U. Behre</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Eron, L J" uniqKey="Eron L">L.J. Eron</name></author><author><name sortKey="Toy, C" uniqKey="Toy C">C. Toy</name></author><author><name sortKey="Salsitz, B" uniqKey="Salsitz B">B. Salsitz</name></author><author><name sortKey="Scheer, R R" uniqKey="Scheer R">R.R. Scheer</name></author><author><name sortKey="Wood, D L" uniqKey="Wood D">D.L. Wood</name></author><author><name sortKey="Nadler, P I" uniqKey="Nadler P">P.I. Nadler</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Levin, M J" uniqKey="Levin M">M.J. Levin</name></author><author><name sortKey="Judson, F N" uniqKey="Judson F">F.N. Judson</name></author><author><name sortKey="Eron, L" uniqKey="Eron L">L. Eron</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Moler, F W" uniqKey="Moler F">F.W. Moler</name></author><author><name sortKey="Steinhart, C M" uniqKey="Steinhart C">C.M. Steinhart</name></author><author><name sortKey="Ohmit, S E" uniqKey="Ohmit S">S.E. Ohmit</name></author><author><name sortKey="Stidham, G L" uniqKey="Stidham G">G.L. Stidham</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Guerguerian, A M" uniqKey="Guerguerian A">A.M. Guerguerian</name></author><author><name sortKey="Gauthier, M" uniqKey="Gauthier M">M. Gauthier</name></author><author><name sortKey="Lebel, M H" uniqKey="Lebel M">M.H. Lebel</name></author><author><name sortKey="Farrell, C A" uniqKey="Farrell C">C.A. Farrell</name></author><author><name sortKey="Lacroix, J" uniqKey="Lacroix J">J. Lacroix</name></author></analytic></biblStruct><biblStruct></biblStruct><biblStruct><analytic><author><name sortKey="Koren, G" uniqKey="Koren G">G. Koren</name></author><author><name sortKey="King, S" uniqKey="King S">S. King</name></author><author><name sortKey="Knowles, S" uniqKey="Knowles S">S. Knowles</name></author><author><name sortKey="Phillips, E" uniqKey="Phillips E">E. Phillips</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Ning, Q" uniqKey="Ning Q">Q. Ning</name></author><author><name sortKey="Brown, D" uniqKey="Brown D">D. Brown</name></author><author><name sortKey="Parodo, J" uniqKey="Parodo J">J. Parodo</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Tan, E L" uniqKey="Tan E">E.L. Tan</name></author><author><name sortKey="Ooi, E E" uniqKey="Ooi E">E.E. Ooi</name></author><author><name sortKey="Lin, C Y" uniqKey="Lin C">C.Y. Lin</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Smee, D F" uniqKey="Smee D">D.F. Smee</name></author><author><name sortKey="Bray, M" uniqKey="Bray M">M. Bray</name></author><author><name sortKey="Huggins, J W" uniqKey="Huggins J">J.W. Huggins</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Cinatl, J" uniqKey="Cinatl J">J. Cinatl</name></author><author><name sortKey="Morgenstern, B" uniqKey="Morgenstern B">B. Morgenstern</name></author><author><name sortKey="Bauer, G" uniqKey="Bauer G">G. Bauer</name></author><author><name sortKey="Chandra, P" uniqKey="Chandra P">P. Chandra</name></author><author><name sortKey="Rabenau, H" uniqKey="Rabenau H">H. Rabenau</name></author><author><name sortKey="Doerr, H W" uniqKey="Doerr H">H.W. Doerr</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Cinatl, J" uniqKey="Cinatl J">J. Cinatl</name></author><author><name sortKey="Morgenstern, B" uniqKey="Morgenstern B">B. Morgenstern</name></author><author><name sortKey="Bauer, G" uniqKey="Bauer G">G. Bauer</name></author><author><name sortKey="Chandra, P" uniqKey="Chandra P">P. Chandra</name></author><author><name sortKey="Rabenau, H" uniqKey="Rabenau H">H. Rabenau</name></author><author><name sortKey="Doerr, H W" uniqKey="Doerr H">H.W. Doerr</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Chen, F" uniqKey="Chen F">F. Chen</name></author><author><name sortKey="Chan, K H" uniqKey="Chan K">K.H. Chan</name></author><author><name sortKey="Jiang, Y" uniqKey="Jiang Y">Y. Jiang</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Kumar, K S" uniqKey="Kumar K">K.S. Kumar</name></author><author><name sortKey="Russo, M W" uniqKey="Russo M">M.W. Russo</name></author><author><name sortKey="Borczuk, A C" uniqKey="Borczuk A">A.C. Borczuk</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Haagmans, B L" uniqKey="Haagmans B">B.L. Haagmans</name></author><author><name sortKey="Kuiken, T" uniqKey="Kuiken T">T. Kuiken</name></author><author><name sortKey="Martina, B E" uniqKey="Martina B">B.E. Martina</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Hensley, L E" uniqKey="Hensley L">L.E. Hensley</name></author><author><name sortKey="Fritz, L E" uniqKey="Fritz L">L.E. Fritz</name></author><author><name sortKey="Jahrling, P B" uniqKey="Jahrling P">P.B. Jahrling</name></author><author><name sortKey="Karp, C L" uniqKey="Karp C">C.L. Karp</name></author><author><name sortKey="Huggins, J W" uniqKey="Huggins J">J.W. Huggins</name></author><author><name sortKey="Geisbert, T W" uniqKey="Geisbert T">T.W. Geisbert</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Stroher, U" uniqKey="Stroher U">U. Stroher</name></author><author><name sortKey="Dicaro, A" uniqKey="Dicaro A">A. DiCaro</name></author><author><name sortKey="Li, Y" uniqKey="Li Y">Y. Li</name></author></analytic></biblStruct></listBibl></div1></back></TEI><pmc article-type="research-article"><pmc-dir>properties open_access</pmc-dir>
<front><journal-meta><journal-id journal-id-type="nlm-ta">J Infect</journal-id><journal-id journal-id-type="iso-abbrev">J. Infect</journal-id><journal-title-group><journal-title>The Journal of Infection</journal-title></journal-title-group><issn pub-type="ppub">0163-4453</issn><issn pub-type="epub">1532-2742</issn><publisher><publisher-name>The British Infection Society. Published by Elsevier Ltd.</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">15474623</article-id><article-id pub-id-type="pmc">7112637</article-id><article-id pub-id-type="publisher-id">S0163-4453(04)00165-3</article-id><article-id pub-id-type="doi">10.1016/j.jinf.2004.07.010</article-id><article-categories><subj-group subj-group-type="heading"><subject>Article</subject></subj-group></article-categories><title-group><article-title>Medical treatment of viral pneumonia including SARS in immunocompetent adult</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Cheng</surname><given-names>V.C.C.</given-names></name><xref rid="aff1" ref-type="aff">a</xref></contrib><contrib contrib-type="author"><name><surname>Tang</surname><given-names>B.S.F.</given-names></name><xref rid="aff1" ref-type="aff">a</xref></contrib><contrib contrib-type="author"><name><surname>Wu</surname><given-names>A.K.L.</given-names></name><xref rid="aff1" ref-type="aff">a</xref></contrib><contrib contrib-type="author"><name><surname>Chu</surname><given-names>C.M.</given-names></name><xref rid="aff2" ref-type="aff">b</xref></contrib><contrib contrib-type="author"><name><surname>Yuen</surname><given-names>K.Y.</given-names></name><email>kyyuen@hkucc.hku.hk</email><xref rid="aff1" ref-type="aff">a</xref><xref rid="cor1" ref-type="corresp">*</xref></contrib></contrib-group><aff id="aff1"><label>a</label>Centre of Infection, Queen Mary Hospital, The University of Hong Kong, Hong Kong Special Administrative Region, China</aff><aff id="aff2"><label>b</label>Department of Medicine, United Christian Hospital, Hong Kong Special Administrative Region, China</aff><author-notes><corresp id="cor1"><label>*</label>Corresponding author. Tel.: +852-2855-4892; fax: +852-2855-1241. <email>kyyuen@hkucc.hku.hk</email></corresp></author-notes><pub-date pub-type="pmc-release"><day>11</day><month>9</month><year>2004</year></pub-date><pmc-comment> PMC Release delay is 0 months and 0 days and was based on .</pmc-comment>
<pub-date pub-type="ppub"><month>11</month><year>2004</year></pub-date><pub-date pub-type="epub"><day>11</day><month>9</month><year>2004</year></pub-date><volume>49</volume><issue>4</issue><fpage>262</fpage><lpage>273</lpage><history><date date-type="accepted"><day>15</day><month>7</month><year>2004</year></date></history><permissions><copyright-statement>Copyright © 2004 The British Infection Society. Published by Elsevier Ltd. All rights reserved.</copyright-statement><copyright-year>2004</copyright-year><copyright-holder>The British Infection Society</copyright-holder><license><license-p>Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.</license-p></license></permissions><abstract><p>Since no randomized controlled trials have been conducted on the treatment of viral pneumonia by antivirals or immunomodulators in immunocompetent adults, a review of such anecdotal experience are needed for the more rational use of such agents. Case reports (single or case series) with details on their treatment and outcome in the English literature can be reviewed for pneumonia caused by human or avian influenza A virus (50 patients), varicella zoster virus (120), adenovirus (29), hantavirus (100) and SARS coronavirus (SARS-CoV) (841). Even with steroid therapy alone, the mortality rate appeared to be lower when compared with conservative treatment for pneumonia caused by human influenza virus (12.5% vs. 42.1%) and hantavirus (13.3% vs. 63.4%). Combination of an effective antiviral, acyclovir, with steroid in the treatment of varicella zoster virus may be associated with a lower mortality than acyclovir alone (0% vs. 10.3%). Combination of interferon alfacon-1 plus steroid, or lopinavir/ritonavir, ribavirin plus steroid were associated with a better outcome than ribavirin plus steroid (0% vs. 2.3% vs. 7.7%, respectively). Combination of lopinavir/ritonavir plus ribavirin significantly reduced the virus load of SARS-CoV in nasopharyngeal, serum, stool and urine specimens taken between day 10 and 15 after symptom onset when compared with the historical control group treated with ribavirin. It appears that the combination of an effective antiviral and steroid was associated with a better outcome. Randomized therapeutic trial should be conducted to ascertain the relative usefulness of antiviral alone or in combination with steroid.</p></abstract><kwd-group><title>Keywords</title><kwd>Viral pneumonia</kwd><kwd>Treatment</kwd><kwd>SARS</kwd><kwd>Immunocompetent host</kwd></kwd-group></article-meta></front><body><sec><label>1</label><title>Introduction</title><p>The start of the new millennium is marked by two emerging infectious diseases coming from wild game food animals and poultry.<xref rid="bib1" ref-type="bibr">1</xref>, <xref rid="bib2" ref-type="bibr">2</xref> Both SARS coronavirus (SARS-CoV) and avian influenza A H5N1 virus predominantly manifest as acute community acquired pneumonia with no response to empirical treatment by antibacterials covering typical and atypical agents.<xref rid="bib3" ref-type="bibr">3</xref>, <xref rid="bib4" ref-type="bibr">4</xref>, <xref rid="bib5" ref-type="bibr">5</xref>, <xref rid="bib6" ref-type="bibr">6</xref>, <xref rid="bib7" ref-type="bibr">7</xref> SARS-CoV and avian influenza A H5N1 pneumonia are associated with significant mortality.<xref rid="bib7" ref-type="bibr">7</xref>, <xref rid="bib8" ref-type="bibr">8</xref>, <xref rid="bib9" ref-type="bibr">9</xref> Unfortunately, few prospective studies have been performed with documentation of the virus load changes during the course of illness for any respiratory viral pneumonia.<xref rid="bib8" ref-type="bibr">8</xref>, <xref rid="bib10" ref-type="bibr">10</xref> The literature on the histological changes or pathogenesis of this condition is scarce. No randomized placebo-controlled treatment trial has ever been conducted. Such lack of data was often attributed to the lack of rapid diagnostic tests and effective antivirals. During the SARS outbreak, the empirical use of ribavirin and steroids were regarded as controversial.<xref rid="bib11" ref-type="bibr">11</xref>, <xref rid="bib12" ref-type="bibr">12</xref>, <xref rid="bib13" ref-type="bibr">13</xref>, <xref rid="bib14" ref-type="bibr">14</xref> Due to the explosive nature of the outbreak, randomized controlled trials on treatment could not be organized. Therefore, we attempt to review the literature on the rationale and strategy used in the treatment of acute community acquired viral pneumonia in immunocompetent adults. Virus load data and serological changes of acute respiratory viral pneumonia available in the literature, as well as from our SARS patients were included in this analysis.</p></sec><sec><label>2</label><title>Materials and methods</title><p>All the case reports and series with clinical details involving medical therapy of viral pneumonia including SARS in patients aged 15 years or above were included in this review. Patients with immunosuppressive conditions such as congenital or acquired immunodeficiencies, solid or marrow transplants, undergoing chemotherapy, and pregnancy were excluded. Where appropriate, the cited bibliographies were also retrieved for analysis.</p><p>Preliminary review of these publications suggested that viral pneumonia caused by SARS-CoV constituted the majority of cases reported in the literature. However, similar to other causes of viral pneumonia, little information on the virus load changes with respect to treatment was systematically reported. Therefore, laboratory data from our cohort of 152 SARS patients who fulfilled the modified WHO definition were retrieved.<xref rid="bib5" ref-type="bibr"><sup>5</sup></xref> Virus load was measured on nasopharyngeal, serum, stool and urine specimens taken between day 10 and 15 after symptom onset. Part of these data was previously reported.<xref rid="bib8" ref-type="bibr">8</xref>, <xref rid="bib10" ref-type="bibr">10</xref>, <xref rid="bib15" ref-type="bibr">15</xref>, <xref rid="bib16" ref-type="bibr">16</xref> The virus load results were correlated with the specific antiviral regimens, namely ribavirin with and without lopinavir/ritonavir for SARS. Serial quantitative RT-PCRs and IgG titers of SARS-CoV were performed in 12 randomly selected patients who were treated with ribavirin and corticosteroid on day 5, 10, 15 and 20 after onset of symptoms. To compare the serial virus load and antibody seroconversion with other respiratory virus infections, the English-language literature was searched to identify studies with detailed description of serial virus load and antibody titers during the course of infection.</p></sec><sec><label>3</label><title>Results</title><p>In the literature review, there were 1997 and 322 English publications on human studies identified in PubMed when the combination of keywords ‘virus, pneumonia, treatment’ and ‘SARS, treatment’ were used on 11 January 2004, respectively. Among the 1997 publications, those related to HIV and AIDS patients (950), cancer and transplant patients (501), and vaccine and immunization topics (287), were excluded. The remaining 259 papers were retrieved and analysed. All the 322 SARS paper were retrieved and analysed. Subsequent PubMed search using the keywords of ‘influenza, pneumonia, treatment’, ‘respiratory syncytial virus, pneumonia, treatment’, ‘varicella, pneumonia, treatment’, ‘adenovirus, pneumonia, treatment’, and ‘hantavirus pulmonary syndrome, treatment’ identified another 623, 267, 240, 146 and 83 papers, respectively. The cited bibliographies, if relevant, were also included in this review. However, only 62 of these 1940 papers contained clinical details and information on the medical treatment of viral pneumonia (44 papers) and SARS (18 papers), respectively.</p><p>Of the 302 patients with non-SARS viral pneumonia in 44 case reports or series (<xref rid="tbl1" ref-type="table">Table 1</xref>), their aetiological diagnoses of human influenza A virus (<italic>n</italic>=38), avian influenza A H5N1 virus (<italic>n</italic>=12), varicella zoster virus (VZV) (<italic>n</italic>=120), adenovirus (<italic>n</italic>=29), hantavirus (<italic>n</italic>=100), respiratory syncytial virus (RSV) (<italic>n</italic>=1), measles virus (<italic>n</italic>=1), and Epstein–Barr virus (EBV) (<italic>n</italic>=1), were documented by a combination of clinical features, radiographic changes, virological and serological tests.<xref rid="bib6" ref-type="bibr">6</xref>, <xref rid="bib7" ref-type="bibr">7</xref>, <xref rid="bib17" ref-type="bibr">17</xref>, <xref rid="bib18" ref-type="bibr">18</xref>, <xref rid="bib19" ref-type="bibr">19</xref>, <xref rid="bib20" ref-type="bibr">20</xref>, <xref rid="bib21" ref-type="bibr">21</xref>, <xref rid="bib22" ref-type="bibr">22</xref>, <xref rid="bib23" ref-type="bibr">23</xref>, <xref rid="bib24" ref-type="bibr">24</xref>, <xref rid="bib25" ref-type="bibr">25</xref>, <xref rid="bib26" ref-type="bibr">26</xref>, <xref rid="bib27" ref-type="bibr">27</xref>, <xref rid="bib28" ref-type="bibr">28</xref>, <xref rid="bib29" ref-type="bibr">29</xref>, <xref rid="bib30" ref-type="bibr">30</xref>, <xref rid="bib31" ref-type="bibr">31</xref>, <xref rid="bib32" ref-type="bibr">32</xref>, <xref rid="bib33" ref-type="bibr">33</xref>, <xref rid="bib34" ref-type="bibr">34</xref>, <xref rid="bib35" ref-type="bibr">35</xref>, <xref rid="bib36" ref-type="bibr">36</xref>, <xref rid="bib37" ref-type="bibr">37</xref>, <xref rid="bib38" ref-type="bibr">38</xref>, <xref rid="bib39" ref-type="bibr">39</xref>, <xref rid="bib40" ref-type="bibr">40</xref>, <xref rid="bib41" ref-type="bibr">41</xref>, <xref rid="bib42" ref-type="bibr">42</xref>, <xref rid="bib43" ref-type="bibr">43</xref>, <xref rid="bib44" ref-type="bibr">44</xref>, <xref rid="bib45" ref-type="bibr">45</xref>, <xref rid="bib46" ref-type="bibr">46</xref>, <xref rid="bib47" ref-type="bibr">47</xref>, <xref rid="bib48" ref-type="bibr">48</xref>, <xref rid="bib49" ref-type="bibr">49</xref>, <xref rid="bib50" ref-type="bibr">50</xref>, <xref rid="bib51" ref-type="bibr">51</xref>, <xref rid="bib52" ref-type="bibr">52</xref>, <xref rid="bib53" ref-type="bibr">53</xref>, <xref rid="bib54" ref-type="bibr">54</xref>, <xref rid="bib55" ref-type="bibr">55</xref>, <xref rid="bib56" ref-type="bibr">56</xref>, <xref rid="bib57" ref-type="bibr">57</xref>, <xref rid="bib58" ref-type="bibr">58</xref> Demographic details were mentioned in 171 (56.6%) patients. There were 113 males and 58 females, with a median age of 31 years (ranged 15–88). The small number of patients suffering from pneumonia caused by RSV, measles, EBV precluded any meaningful analysis or discussion.<xref rid="bib56" ref-type="bibr">56</xref>, <xref rid="bib57" ref-type="bibr">57</xref>, <xref rid="bib58" ref-type="bibr">58</xref> As for the other agents, the overall mortality ranges from 9.2% (VZV), 20.7% (adenovirus), 31.6% (human influenza A virus), 49% (hantavirus) to 66.7% (avian influenza A H5N1 virus).<table-wrap position="float" id="tbl1"><label>Table 1</label><caption><p>Summary of literature reported cases in the medical management of viral pneumonia other than SARS in immunocompetent host</p></caption><table frame="hsides" rules="groups"><thead><tr><th>Antiviral therapies and/or immunomodulating agents with respect to different viral pathogens; sex & age (if mentioned)</th><th>Number of cases</th><th>Mechanical ventilation (%)</th><th>Mortality (%)</th><th>Reference</th></tr></thead><tbody><tr><td><italic>Human influenza A pneumonia</italic>—8 M/8 F; median age 65 years (23–80 years)</td><td align="char">38</td><td>24 (63.2)</td><td>12 (31.6%)</td><td><xref rid="bib17" ref-type="bibr">17</xref>, <xref rid="bib18" ref-type="bibr">18</xref>, <xref rid="bib19" ref-type="bibr">19</xref>, <xref rid="bib20" ref-type="bibr">20</xref>, <xref rid="bib21" ref-type="bibr">21</xref>, <xref rid="bib22" ref-type="bibr">22</xref>, <xref rid="bib23" ref-type="bibr">23</xref></td></tr><tr><td> Conservative treatment</td><td align="char">19</td><td>12 (63.2%)</td><td>8 (42.1%)</td><td>17–20</td></tr><tr><td> Antiviral alone: Rimantadine (1), oseltamivir (5), combination of oseltamivir and rimantadine (5)</td><td align="char">11</td><td>8 (72.7%)</td><td>3 (27.3%)</td><td><xref rid="bib20" ref-type="bibr">20</xref>, <xref rid="bib22" ref-type="bibr">22</xref>, <xref rid="bib23" ref-type="bibr">23</xref></td></tr><tr><td> Corticosteroid alone: MP 500 mg IVI q6 h (1); hydrocortisone 250 mg IVI q4 h and tailing from day 6 to day 26 after admission (1)</td><td align="char">8</td><td>4 (50%)</td><td>1 (12.5%)</td><td><xref rid="bib20" ref-type="bibr">20</xref>, <xref rid="bib21" ref-type="bibr">21</xref>, <xref rid="bib22" ref-type="bibr">22</xref></td></tr><tr><td>
<italic>Avian influenza A H5N1 pneumonia</italic>—6 M/6 F; median age of 24.5 years (16–60 years)</td><td align="char">12</td><td>6 (50%)</td><td>8 (66.7%)</td><td><xref rid="bib6" ref-type="bibr">6</xref>, <xref rid="bib7" ref-type="bibr">7</xref>, <xref rid="bib24" ref-type="bibr">24</xref>, <xref rid="bib25" ref-type="bibr">25</xref></td></tr><tr><td> Conservative treatment</td><td align="char">2</td><td>0 (0%)</td><td>1 (50%)</td><td><xref rid="bib24" ref-type="bibr">24</xref></td></tr><tr><td> Antiviral alone: Amantadine (4), oseltamivir (3)</td><td align="char">7</td><td>3 (42.9%)</td><td>5 (71.4%)</td><td><xref rid="bib6" ref-type="bibr">6</xref>, <xref rid="bib24" ref-type="bibr">24</xref>, <xref rid="bib25" ref-type="bibr">25</xref></td></tr><tr><td> Antiviral and immunomodulators: Amantadine for 3 days and steroid in 1; oseltamivir for 5 days and MP 1–2 mg/kg IVI q6 h for 3 and 4 days in 2 patients, respectively</td><td align="char">3</td><td>3 (100%)</td><td>2 (66.7%)</td><td><xref rid="bib6" ref-type="bibr">6</xref>, <xref rid="bib7" ref-type="bibr">7</xref></td></tr><tr><td>
<italic>VZV pneumonia</italic>—61 M/28 F; median age of 31 years (22–88 years)</td><td align="char">120</td><td>37 (30.8%)</td><td>11 (9.2%)</td><td><xref rid="bib26" ref-type="bibr">26</xref>, <xref rid="bib27" ref-type="bibr">27</xref>, <xref rid="bib28" ref-type="bibr">28</xref>, <xref rid="bib29" ref-type="bibr">29</xref>, <xref rid="bib30" ref-type="bibr">30</xref>, <xref rid="bib31" ref-type="bibr">31</xref>, <xref rid="bib32" ref-type="bibr">32</xref>, <xref rid="bib33" ref-type="bibr">33</xref>, <xref rid="bib34" ref-type="bibr">34</xref>, <xref rid="bib35" ref-type="bibr">35</xref>, <xref rid="bib36" ref-type="bibr">36</xref>, <xref rid="bib37" ref-type="bibr">37</xref>, <xref rid="bib38" ref-type="bibr">38</xref>, <xref rid="bib39" ref-type="bibr">39</xref>, <xref rid="bib40" ref-type="bibr">40</xref>, <xref rid="bib41" ref-type="bibr">41</xref>, <xref rid="bib42" ref-type="bibr">42</xref>, <xref rid="bib43" ref-type="bibr">43</xref></td></tr><tr><td> Conservative treatment</td><td align="char">33</td><td>2 (6.1%)</td><td>4 (12.1%)</td><td><xref rid="bib26" ref-type="bibr">26</xref>, <xref rid="bib27" ref-type="bibr">27</xref>, <xref rid="bib28" ref-type="bibr">28</xref>, <xref rid="bib29" ref-type="bibr">29</xref></td></tr><tr><td> Antiviral alone: Intravenous acyclovir (66), vidarabine (2)</td><td align="char">68</td><td>26 (38.2%)</td><td>7 (10.3%)</td><td><xref rid="bib27" ref-type="bibr">27</xref>, <xref rid="bib28" ref-type="bibr">28</xref>, <xref rid="bib29" ref-type="bibr">29</xref>, <xref rid="bib30" ref-type="bibr">30</xref>, <xref rid="bib31" ref-type="bibr">31</xref>, <xref rid="bib32" ref-type="bibr">32</xref>, <xref rid="bib33" ref-type="bibr">33</xref>, <xref rid="bib34" ref-type="bibr">34</xref>, <xref rid="bib35" ref-type="bibr">35</xref>, <xref rid="bib36" ref-type="bibr">36</xref>, <xref rid="bib37" ref-type="bibr">37</xref>, <xref rid="bib38" ref-type="bibr">38</xref></td></tr><tr><td> Antiviral and immunomodulators: intravenous acyclovir and corticosteroid (17), intravenous acyclovir and IVIG (2) (hydrocortisone 200 mg IVI q6 h for 2 days in 6; hydrocortisone 100 mg IVI q6 h and tailing over 1 month in 1; P 60 mg po qd and tailing over 32 weeks in 1; MP 60 mg IVI q6 h for 2 days in 1 patient)</td><td align="char">19</td><td>9 (47.4%)</td><td>0 (0%)</td><td><xref rid="bib28" ref-type="bibr">28</xref>, <xref rid="bib29" ref-type="bibr">29</xref>, <xref rid="bib39" ref-type="bibr">39</xref>, <xref rid="bib40" ref-type="bibr">40</xref>, <xref rid="bib41" ref-type="bibr">41</xref>, <xref rid="bib42" ref-type="bibr">42</xref>, <xref rid="bib43" ref-type="bibr">43</xref></td></tr><tr><td>
<italic>Adenoviral pneumonia</italic>—7 M/3 F; median age of 22 years (18–48 years)</td><td align="char">29</td><td>12 (41.4%)</td><td>6 (20.7%)</td><td><xref rid="bib21" ref-type="bibr">21</xref>, <xref rid="bib44" ref-type="bibr">44</xref>, <xref rid="bib45" ref-type="bibr">45</xref>, <xref rid="bib46" ref-type="bibr">46</xref>, <xref rid="bib47" ref-type="bibr">47</xref>, <xref rid="bib48" ref-type="bibr">48</xref>, <xref rid="bib49" ref-type="bibr">49</xref>, <xref rid="bib50" ref-type="bibr">50</xref></td></tr><tr><td> Conservative treatment</td><td align="char">25</td><td>10 (34.5%)</td><td>4 (16%)</td><td><xref rid="bib44" ref-type="bibr">44</xref>, <xref rid="bib45" ref-type="bibr">45</xref>, <xref rid="bib46" ref-type="bibr">46</xref>, <xref rid="bib47" ref-type="bibr">47</xref>, <xref rid="bib48" ref-type="bibr">48</xref></td></tr><tr><td> Corticosteroid alone</td><td align="char">4</td><td>2 (50%)</td><td>2 (50%)</td><td><xref rid="bib21" ref-type="bibr">21</xref>, <xref rid="bib44" ref-type="bibr">44</xref>, <xref rid="bib49" ref-type="bibr">49</xref>, <xref rid="bib50" ref-type="bibr">50</xref></td></tr><tr><td>
<italic>Hantavirus pulmonary syndrome</italic>—30 M/11 F; median age of 33 years (15–63 years)</td><td align="char">100</td><td>25/56 (44.6%)</td><td>49 (49%)</td><td><xref rid="bib51" ref-type="bibr">51</xref>, <xref rid="bib52" ref-type="bibr">52</xref>, <xref rid="bib53" ref-type="bibr">53</xref>, <xref rid="bib54" ref-type="bibr">54</xref>, <xref rid="bib55" ref-type="bibr">55</xref></td></tr><tr><td> Conservative treatment</td><td align="char">41</td><td>18/26 (69.2%)</td><td>26 (63.4%)</td><td><xref rid="bib51" ref-type="bibr">51</xref>, <xref rid="bib52" ref-type="bibr">52</xref>, <xref rid="bib53" ref-type="bibr">53</xref></td></tr><tr><td> Antiviral alone: intravenous ribavirin</td><td align="char">44</td><td>NM</td><td>21 (47.7%)</td><td><xref rid="bib51" ref-type="bibr">51</xref>, <xref rid="bib54" ref-type="bibr">54</xref>, <xref rid="bib55" ref-type="bibr">55</xref><xref rid="tblfn1" ref-type="table-fn">a</xref></td></tr><tr><td> Corticosteroid alone</td><td align="char">15</td><td>7 (46.7%)</td><td>2 (13.3%)</td><td><xref rid="bib52" ref-type="bibr">52</xref>, <xref rid="bib53" ref-type="bibr">53</xref></td></tr><tr><td>
<italic>RSV pneumonia</italic>—F/64; aerosolized ribavirin 6 gm 22 hours daily for 5 days</td><td align="char">1</td><td>1 (100%)</td><td>0</td><td><xref rid="bib56" ref-type="bibr">56</xref></td></tr><tr><td>
<italic>Measles pneumonia</italic>—F/29; MP 1 gm IVI daily for 2 days and tailing dose thereafter; vitamin A 200 000 U orally for 2 days</td><td align="char">1</td><td>1 (100%)</td><td>0</td><td><xref rid="bib57" ref-type="bibr">57</xref></td></tr><tr><td>
<italic>EBV pneumonia</italic>—M/30; P 100 mg po daily for 11 days then tailing gradually</td><td align="char">1</td><td>1 (100%)</td><td>0</td><td><xref rid="bib58" ref-type="bibr">58</xref></td></tr></tbody></table><table-wrap-foot><fn><p>EBV, Epstein–Barr virus; MP, methylprednisolone; NM, not mention; P, prednisolone; IVI, intravenously; IVIG, intravenous immunoglobulin; RSV, respiratory syncytial virus; VZV, varicella-zoster virus.</p></fn></table-wrap-foot><table-wrap-foot><fn id="tblfn1"><label>a</label><p>Patients described in Ref. <xref rid="bib55" ref-type="bibr">55</xref> were also reported in Ref. <xref rid="bib54" ref-type="bibr">54</xref>.</p></fn></table-wrap-foot></table-wrap></p><p>In the treatment of human influenza A infection, antiviral agents such as rimantadine (one patient), oseltamivir (five patients), and a combination of rimantadine and oseltamivir had been used at a median of 3 days (ranged 1–7 days) after admission.<xref rid="bib20" ref-type="bibr">20</xref>, <xref rid="bib21" ref-type="bibr">21</xref>, <xref rid="bib22" ref-type="bibr">22</xref>, <xref rid="bib23" ref-type="bibr">23</xref> High dose corticosteroid without antiviral therapy was also attempted.<xref rid="bib20" ref-type="bibr">20</xref>, <xref rid="bib21" ref-type="bibr">21</xref>, <xref rid="bib22" ref-type="bibr">22</xref> The dose of steroids ranged from hydrocortisone 250 mg IVI every 4 hourly to methylprednisolone 500 mg IVI every 6 hourly.<xref rid="bib21" ref-type="bibr">21</xref>, <xref rid="bib22" ref-type="bibr">22</xref> Amantadine (four patients), oseltamivir (three patients), and a combination of antivirals and corticosteroid (three patients) had also been used in the treatment of avian influenza A H5N1 infection.<xref rid="bib6" ref-type="bibr">6</xref>, <xref rid="bib7" ref-type="bibr">7</xref> There was no apparent benefit since the antiviral agents were started at a median of 5 days (ranged 0–5 days) after admission. Corticosteroid such as intravenous methylprednisolone 1–2 mg/kg every 6 hourly for 3–4 days had been given in three mechanically ventilated patients but two of them died of acute respiratory distress syndrome (ARDS).<xref rid="bib6" ref-type="bibr">6</xref>, <xref rid="bib7" ref-type="bibr">7</xref></p><p>As for VZV pneumonia, antiviral therapy including intravenous acyclovir 10–15 mg/kg every 8 hourly for 7–10 days was initiated in 66 out of 120 patients.<xref rid="bib26" ref-type="bibr">26</xref>, <xref rid="bib27" ref-type="bibr">27</xref>, <xref rid="bib28" ref-type="bibr">28</xref>, <xref rid="bib29" ref-type="bibr">29</xref>, <xref rid="bib30" ref-type="bibr">30</xref>, <xref rid="bib31" ref-type="bibr">31</xref>, <xref rid="bib32" ref-type="bibr">32</xref>, <xref rid="bib33" ref-type="bibr">33</xref>, <xref rid="bib34" ref-type="bibr">34</xref>, <xref rid="bib35" ref-type="bibr">35</xref>, <xref rid="bib36" ref-type="bibr">36</xref>, <xref rid="bib37" ref-type="bibr">37</xref>, <xref rid="bib38" ref-type="bibr">38</xref> Two patients were treated with vidarabine before the widespread use of acyclovir.<xref rid="bib27" ref-type="bibr">27</xref>, <xref rid="bib38" ref-type="bibr">38</xref> Corticosteroids were combined with acyclovir in 17 patients.<xref rid="bib28" ref-type="bibr">28</xref>, <xref rid="bib29" ref-type="bibr">29</xref>, <xref rid="bib39" ref-type="bibr">39</xref>, <xref rid="bib40" ref-type="bibr">40</xref>, <xref rid="bib41" ref-type="bibr">41</xref> The dosage and duration of steroids were quite variable (<xref rid="tbl1" ref-type="table">Table 1</xref>).<xref rid="bib29" ref-type="bibr">29</xref>, <xref rid="bib39" ref-type="bibr">39</xref>, <xref rid="bib40" ref-type="bibr">40</xref>, <xref rid="bib41" ref-type="bibr">41</xref> Two patients received intravenous immunoglobulin (IVIG) together with intravenous acyclovir had a favorable outcome.<xref rid="bib42" ref-type="bibr">42</xref>, <xref rid="bib43" ref-type="bibr">43</xref> The mortality of patients who received acyclovir or vidarabine alone was seven out of 68 (10.3%), whereas four patients managed with supportive care died. Only one out of 25 patients died if intravenous acyclovir was initiated within 4 days of admission.<xref rid="bib27" ref-type="bibr">27</xref>, <xref rid="bib34" ref-type="bibr">34</xref>, <xref rid="bib35" ref-type="bibr">35</xref> There was no death in patients treated with a combination of acyclovir and immunomodulators such as corticosteroid and IVIG.<xref rid="bib28" ref-type="bibr">28</xref>, <xref rid="bib29" ref-type="bibr">29</xref>, <xref rid="bib39" ref-type="bibr">39</xref>, <xref rid="bib40" ref-type="bibr">40</xref>, <xref rid="bib41" ref-type="bibr">41</xref>, <xref rid="bib42" ref-type="bibr">42</xref>, <xref rid="bib43" ref-type="bibr">43</xref></p><p>As for adenoviral pneumonia, no antiviral was ever used for their treatment. Two of four (50%) patient receiving steroid died, which appeared to be higher than patients managed conservatively.<xref rid="bib21" ref-type="bibr">21</xref>, <xref rid="bib44" ref-type="bibr">44</xref>, <xref rid="bib45" ref-type="bibr">45</xref>, <xref rid="bib46" ref-type="bibr">46</xref>, <xref rid="bib47" ref-type="bibr">47</xref>, <xref rid="bib48" ref-type="bibr">48</xref>, <xref rid="bib49" ref-type="bibr">49</xref>, <xref rid="bib50" ref-type="bibr">50</xref> The mortality for hantavirus pulmonary syndrome treated with intravenous ribavirin (47.7%) appeared to be only slightly lower than those treated conservatively (63.4%).<xref rid="bib51" ref-type="bibr">51</xref>, <xref rid="bib52" ref-type="bibr">52</xref>, <xref rid="bib53" ref-type="bibr">53</xref>, <xref rid="bib54" ref-type="bibr">54</xref>, <xref rid="bib55" ref-type="bibr">55</xref> The use of methylprednisolone was associated with a dramatic decrease of mortality to 13.3%.<xref rid="bib52" ref-type="bibr">52</xref>, <xref rid="bib53" ref-type="bibr">53</xref></p><p>Though there were 849 cases of SARS with treatment details reported in the literature, many of these patients were diagnosed according to the clinical criteria issued by WHO with or without laboratory confirmation (<xref rid="tbl2" ref-type="table">Table 2</xref>).<xref rid="bib3" ref-type="bibr">3</xref>, <xref rid="bib4" ref-type="bibr">4</xref>, <xref rid="bib5" ref-type="bibr">5</xref>, <xref rid="bib8" ref-type="bibr">8</xref>, <xref rid="bib10" ref-type="bibr">10</xref>, <xref rid="bib59" ref-type="bibr">59</xref>, <xref rid="bib60" ref-type="bibr">60</xref>, <xref rid="bib61" ref-type="bibr">61</xref>, <xref rid="bib62" ref-type="bibr">62</xref>, <xref rid="bib63" ref-type="bibr">63</xref>, <xref rid="bib64" ref-type="bibr">64</xref>, <xref rid="bib65" ref-type="bibr">65</xref>, <xref rid="bib66" ref-type="bibr">66</xref>, <xref rid="bib67" ref-type="bibr">67</xref>, <xref rid="bib68" ref-type="bibr">68</xref>, <xref rid="bib69" ref-type="bibr">69</xref>, <xref rid="bib70" ref-type="bibr">70</xref>, <xref rid="bib71" ref-type="bibr">71</xref> One of the case series was not included because patients treated by different treatment regimens were aggregated together and could not be analysed.<xref rid="bib72" ref-type="bibr"><sup>72</sup></xref> There were 349 males and 500 females. Except for 13 (1.5%) patients who were treated conservatively, antiviral therapy and/or immunomodulating therapy were given in all other patients. Of 772 patients receiving specific antiviral therapy and/or immunomodulating therapy, 675 (87.4%) were treated with ribavirin containing regimens and 44 (5.7%) were treated with lopinavir/ritonavir containing regimens during the initial phase of the disease. Immunomodulating therapy without antiviral agents was initiated in 53 of 772 (6.9%) patients. Recombinant interferon alpha, corticosteroid, and a combination of interferon alfacon-1 and corticosteroid were used in 30 (3.9%), 14 (1.8%) and 9 (1.2%) cases, respectively. Of the 64 patients receiving treatment during clinical deterioration, ribavirin or oseltamivir, lopinavir/ritonavir, and convalescent plasma were given as rescue medical therapy in 32 (50%), 31 (48.4%) and 1 (1.6%), respectively. High dose pulse methylprednisolone was used during clinical deterioration such as oxygen desaturation, worsening of radiographic infiltrates in the chest, recurrent fever without evidence of nosocomial sepsis in some reports. However, the number of patients requiring pulse steroids was not mentioned in most of them.<xref rid="bib5" ref-type="bibr">5</xref>, <xref rid="bib8" ref-type="bibr">8</xref>, <xref rid="bib10" ref-type="bibr">10</xref>, <xref rid="bib59" ref-type="bibr">59</xref>, <xref rid="bib60" ref-type="bibr">60</xref>, <xref rid="bib61" ref-type="bibr">61</xref>, <xref rid="bib62" ref-type="bibr">62</xref> Furthermore, IVIG, thymic peptides, and recombinant human thymus proteins were used in some patients but the clinical details were not sufficient for any meaningful analysis.<xref rid="bib61" ref-type="bibr"><sup>61</sup></xref> The overall mortality was 7.7% in these 849 SARS cases. No obvious difference was noted irrespective of whether the patients were treated by ribavirin with or without corticosteroids, corticosteroids alone, or recombinant interferon-alpha given on admission or during deterioration. However, the mortality is only 2.3% in a group of 44 patients treated by lopinavir/ritonavir, ribavirin and corticosteroids,<xref rid="bib64" ref-type="bibr"><sup>64</sup></xref> and 0% for nine patients treated with interferon alfacon-1 and corticosteroids.<xref rid="bib65" ref-type="bibr"><sup>65</sup></xref> Only one patient received convalescent plasma as rescue therapy.<xref rid="bib67" ref-type="bibr"><sup>67</sup></xref><table-wrap position="float" id="tbl2"><label>Table 2</label><caption><p>Summary of literature reported cases in the medical management of SARS in adult</p></caption><table frame="hsides" rules="groups"><thead><tr><th>Antiviral therapies and/or immunomodulating agents, in addition to empirical broad spectrum antibiotics therapy</th><th>Number of cases</th><th>Sex (M:F)</th><th>Non-invasive ventilation (%)</th><th>Mechanical ventilation (%)</th><th>Pulse MP for clinical deterioration (%)</th><th>Mortality (%)</th><th>Reference</th></tr></thead><tbody><tr><td>Conservative supportive treatment</td><td align="char">13</td><td>7:6</td><td>0</td><td>4 (30.8%)</td><td>0</td><td>2 (15.4%)</td><td><xref rid="bib3" ref-type="bibr">3</xref>, <xref rid="bib5" ref-type="bibr">5</xref>, <xref rid="bib59" ref-type="bibr">59</xref>, <xref rid="bib60" ref-type="bibr">60</xref>, <xref rid="bib68" ref-type="bibr">68</xref>, <xref rid="bib69" ref-type="bibr">69</xref>, <xref rid="bib70" ref-type="bibr">70</xref>, <xref rid="bib71" ref-type="bibr">71</xref></td></tr><tr><td colspan="8">
<italic>Initial medical management (n=772)</italic></td></tr><tr><td> Ribavirin with or without oseltamivir</td><td align="char">47</td><td>19:28</td><td>10 (21.3%)</td><td>6 (12.8%)</td><td>0</td><td>3 (6.4%)</td><td><xref rid="bib3" ref-type="bibr">3</xref></td></tr><tr><td> Ribavirin and corticosteroid</td><td align="char">611</td><td>263:348</td><td>4 (0.7%)</td><td>104 (17%)</td><td>54/95 (56.8%)</td><td>47 (7.7%)</td><td><xref rid="bib4" ref-type="bibr">4</xref>, <xref rid="bib5" ref-type="bibr">5</xref>, <xref rid="bib8" ref-type="bibr">8</xref>, <xref rid="bib59" ref-type="bibr">59</xref>, <xref rid="bib60" ref-type="bibr">60</xref>, <xref rid="bib61" ref-type="bibr">61</xref>, <xref rid="bib62" ref-type="bibr">62</xref>, <xref rid="bib63" ref-type="bibr">63</xref></td></tr><tr><td> Ribavirin and high dose pulse MP</td><td align="char">17</td><td>7:10</td><td>0</td><td>1 (5.9%)</td><td>4 (23.5%)</td><td>1 (5.9%)</td><td><xref rid="bib63" ref-type="bibr">63</xref></td></tr><tr><td> Lopinavir/ritonavir, ribavirin and corticosteroid</td><td align="char">44</td><td>12:32</td><td>0</td><td>0</td><td>12 (27.3%)</td><td>1 (2.3%)</td><td><xref rid="bib10" ref-type="bibr">10</xref><xref rid="tblfn2" ref-type="table-fn">a</xref>,<xref rid="bib64" ref-type="bibr">64</xref></td></tr><tr><td> Corticosteroid</td><td align="char">14</td><td>3:11</td><td>0</td><td>3 (21.4%)</td><td>2 (14.3%)</td><td>1 (7.1%)</td><td><xref rid="bib65" ref-type="bibr">65</xref>, <xref rid="bib68" ref-type="bibr">68</xref></td></tr><tr><td> Interferon alfacon-1 and corticosteroid</td><td align="char">9</td><td>3:6</td><td>0</td><td>1 (11.1%)</td><td>5 (55.6%)</td><td>0</td><td><xref rid="bib65" ref-type="bibr">65</xref></td></tr><tr><td> Recombinant interferon alpha</td><td align="char">30</td><td>11:19</td><td>8 (26.7%)</td><td>2 (6.7%)</td><td>0</td><td>2 (6.7%)</td><td><xref rid="bib61" ref-type="bibr">61</xref></td></tr><tr><td colspan="8">
<italic>Rescue medical treatment (n=64)</italic></td></tr><tr><td> Ribavirin or oseltamivir</td><td align="char">20</td><td>5:15</td><td>0</td><td>6 (30%)</td><td>0</td><td>3 (15%)</td><td><xref rid="bib66" ref-type="bibr">66</xref></td></tr><tr><td> Ribavirin and corticosteroid</td><td align="char">12</td><td>6:6</td><td>0</td><td>12 (100%)</td><td>NM</td><td>1 (8.3%)</td><td><xref rid="bib5" ref-type="bibr">5</xref></td></tr><tr><td> Convalescent plasma</td><td align="char">1</td><td>F</td><td>0</td><td>0</td><td>1 (100%)</td><td>0</td><td><xref rid="bib67" ref-type="bibr">67</xref></td></tr><tr><td> Lopinavir/ritonavir</td><td align="char">31</td><td>13:18</td><td>0</td><td>3 (9.7%)</td><td>31 (100%)</td><td>4 (12.9%)</td><td><xref rid="bib64" ref-type="bibr">64</xref></td></tr></tbody></table><table-wrap-foot><fn><p>MP, methylprednisolone; SARS, severe acute respiratory syndrome; SARS-CoV, SARS associated coronavirus.</p></fn></table-wrap-foot><table-wrap-foot><fn id="tblfn2"><label>a</label><p>Twelve patients reported in Ref. <xref rid="bib10" ref-type="bibr">10</xref> were included in Ref. <xref rid="bib64" ref-type="bibr">64</xref>.</p></fn></table-wrap-foot></table-wrap></p><p>Of the 152 SARS patients in our cohort, their clinical presentation, virological test results, and treatment regimens have been previously reported.<xref rid="bib8" ref-type="bibr">8</xref>, <xref rid="bib10" ref-type="bibr">10</xref>, <xref rid="bib16" ref-type="bibr">16</xref> The virus load of their nasopharyngeal, serum, stool, and urine specimens collected between day 10 and 15 after onset of symptoms are tabulated in <xref rid="tbl3" ref-type="table">Table 3</xref>. There was no significant relationship between virus load, age, and the presence of co-morbidities. However, significant decreases in virus load were observed when lopinavir/ritonavir was added to ribavirin (<xref rid="tbl3" ref-type="table">Table 3</xref>). It is also interesting to note that stool virus load is significantly higher in males (7.0 vs. 5.5 log<sub>10</sub> copies/ml, <italic>P</italic>=0.02), whereas that of the urine is significantly higher in females (1.6 vs. 0.6 log<sub>10</sub> copies/ml, <italic>P</italic>=0.01). Of the 111 (73%) historical controls treated with ribavirin and corticosteroids, 12 randomly selected patients had serial virus load studies performed on their nasopharyngeal specimens; their mean virus loads were 5.2, 7.3, 4.9 and 3.8 log<sub>10</sub> copies/ml at day 5, 10, 15 and 20 after onset of symptoms, respectively (<xref rid="fig1" ref-type="fig">Fig. 1</xref>). The decline in virus load in nasopharyngeal specimens coincided with the appearance of IgG antibody titers against SARS-CoV during the course of infection (<xref rid="fig2" ref-type="fig">Fig. 2</xref>). Since similar clinical studies of other respiratory viral pneumonias were not available in the literature except for a naturally occurring case of influenza,<xref rid="bib73" ref-type="bibr"><sup>73</sup></xref> another 12 cases of experimental infection with RSV by artificial inoculation into healthy volunteers were adopted for comparison (<xref rid="fig2" ref-type="fig">Fig. 2</xref>).<xref rid="bib74" ref-type="bibr"><sup>74</sup></xref> The virus load of influenza A virus and RSV peaked at day 2 and 3, respectively, whereas that of SARS-CoV occurred at day 10 after onset of symptoms (<xref rid="fig1" ref-type="fig">Fig. 1</xref>). As for the antibody response, baseline antibodies of influenza A virus and RSV were detectable in serum and nasal washings but antibodies against SARS-CoV were not present until day 10 after symptom onset.<table-wrap position="float" id="tbl3"><label>Table 3</label><caption><p>Correlation of demographic data, treatment intervention, and quantitative RT-PCR of clinical specimens between day 10 and 15 in 152 patients with SARS</p></caption><table frame="hsides" rules="groups"><thead><tr><th>Demographic data and treatment intervention</th><th colspan="4">Mean (SD) virus load (log<sub>10</sub> copies/ml)<hr></hr></th></tr><tr><th></th><th>Nasopharyngeal specimens (<italic>n</italic>=152)</th><th>Serum (<italic>n</italic>=53)</th><th>Stool (<italic>n</italic>=94)</th><th>Urine (<italic>n</italic>=111)</th></tr></thead><tbody><tr><td colspan="5"><italic>Age</italic></td></tr><tr><td> Age equal or more than 60 years (<italic>n</italic>=20)</td><td>2.5 (3.0)</td><td>1.2 (1.3)</td><td>6.7 (3.4)</td><td>1.4 (2.3)</td></tr><tr><td> Age less than 60 years (<italic>n</italic>=132)</td><td>2.3 (3.1)</td><td>1.1 (1.5)</td><td>6.0 (3.0)</td><td>1.3 (2.1)</td></tr><tr><td> <italic>P</italic> value</td><td>0.83</td><td>0.96</td><td>0.46</td><td>0.84</td></tr><tr><td colspan="5">
<italic>Sex</italic></td></tr><tr><td> Male (<italic>n</italic>=58)</td><td>2.9 (3.3)</td><td>1.4 (1.4)</td><td>7.0 (2.6)</td><td>0.6 (1.6)</td></tr><tr><td> Female (<italic>n</italic>=94)</td><td>2.0 (2.9)</td><td>1.0 (1.4)</td><td>5.5 (3.2)</td><td>1.6 (2.3)</td></tr><tr><td> <italic>P</italic> value</td><td>0.11</td><td>0.44</td><td>0.02</td><td>0.01</td></tr><tr><td colspan="5">
<italic>Co-morbidity</italic></td></tr><tr><td> Presence of co-morbidity (<italic>n</italic>=28)</td><td>2.9 (3.3)</td><td>1.1 (1.7)</td><td>5.9 (3.4)</td><td>1.2 (2.1)</td></tr><tr><td> Absence of co-morbidity (<italic>n</italic>=124)</td><td>2.2 (3.0)</td><td>1.1 (1.4)</td><td>6.1 (3.0)</td><td>1.3 (2.1)</td></tr><tr><td> <italic>P</italic> value</td><td>0.31</td><td>0.89</td><td>0.78</td><td>0.79</td></tr><tr><td colspan="5">
<italic>Lopinavir/ritonavir therapy in addition to ribavirin</italic></td></tr><tr><td> Presence of lopinavir/ritonavir therapy (<italic>n</italic>=41)</td><td>1.3 (2.6)</td><td>0.4 (0.9)</td><td>4.3 (3.3)</td><td>0.5 (1.4)</td></tr><tr><td> Absence of lopinavir/ritonavir therapy (<italic>n</italic>=111)</td><td>2.8 (3.1)</td><td>1.4 (1.5)</td><td>6.9 (2.6)</td><td>1.7 (2.3)</td></tr><tr><td> <italic>P</italic> value</td><td><0.01</td><td>0.04</td><td><0.01</td><td><0.01</td></tr></tbody></table></table-wrap><fig id="fig1"><label>Figure 1</label><caption><p>Sequential quantitative measurements of viral shedding from upper respiratory tract during infections with influenza A virus, respiratory syncytial virus (RSV), and SARS coronavirus (SARS-CoV). Influenza A virus quantitation was performed on throat washings from a naturally occurring case of influenza in a 28-year-old male. Influenza A/Victoria H3N2 virus was isolated using cell cultures.<xref rid="bib73" ref-type="bibr"><sup>73</sup></xref> RSV quantitation was done on nasal washings from 12 subjects inoculated nasally with 10<sup>4.7</sup> TCID<sub>50</sub> (50 median tissue culture infectious dose) RSV A2 challenge pool of virus, developed by the National Institute of Allergy and Infectious Diseases. RSV virus load was measured by quantitative RT-PCR using primers based on the nucleotide sequences from the F gene of RSV group A and B viruses.<xref rid="bib74" ref-type="bibr"><sup>74</sup></xref> SARS-CoV quantitation was performed on nasopharyngeal specimens from infected patients. SARS-CoV virus load of 12 patients are measured by quantitative RT-PCR of <italic>Pol</italic> gene from nasopharyngeal specimens.</p></caption><graphic xlink:href="gr1"></graphic></fig><fig id="fig2"><label>Figure 2</label><caption><p>Changing titers of serum antibody of influenza A virus, nasal IgA of RSV, and IgG of SARS-CoV after onset of symptoms. Serum antibody titer (HAI) of influenza A virus was determined using serial sera from a patient who was naturally infected with influenza A virus (same patient as shown in <xref rid="fig1" ref-type="fig">Fig. 1</xref>). Mean RSV nasal IgA titers were obtained from nasal washings of 12 subjects who were inoculated with RSV (same group of patients as shown in <xref rid="fig1" ref-type="fig">Fig. 1</xref>). Mean IgG titers of SARS-CoV were obtained using sera from 12 patients who were infected with SARS-CoV (same group of patients as shown in <xref rid="fig1" ref-type="fig">Fig. 1</xref>).</p></caption><graphic xlink:href="gr2"></graphic></fig></p></sec><sec><label>4</label><title>Discussion</title><p>Despite exhaustive laboratory investigations, an aetiological agent could be identified in only around half of the patients suffering from acute community acquired pneumonia.<xref rid="bib75" ref-type="bibr"><sup>75</sup></xref> In immunocompetent adults with community acquired pneumonia, pyogenic bacteria still constitute the majority of microbiologically documented agents in prospective studies.<xref rid="bib76" ref-type="bibr">76</xref>, <xref rid="bib77" ref-type="bibr">77</xref> The lack of readily available rapid diagnostic tests for respiratory viral infections is one of the major reasons for the lack of reports on the natural history, pathogenesis, and treatment of viral pneumonia. Well-documented treatment regimens by randomized control trials are only available for HIV, HCV, HBV, HSV, VZV, CMV and human influenza without pneumonia.<xref rid="bib78" ref-type="bibr">78</xref>, <xref rid="bib79" ref-type="bibr">79</xref>, <xref rid="bib80" ref-type="bibr">80</xref>, <xref rid="bib81" ref-type="bibr">81</xref>, <xref rid="bib82" ref-type="bibr">82</xref>, <xref rid="bib83" ref-type="bibr">83</xref>, <xref rid="bib84" ref-type="bibr">84</xref>, <xref rid="bib85" ref-type="bibr">85</xref>, <xref rid="bib86" ref-type="bibr">86</xref>, <xref rid="bib87" ref-type="bibr">87</xref>, <xref rid="bib88" ref-type="bibr">88</xref>, <xref rid="bib89" ref-type="bibr">89</xref>, <xref rid="bib90" ref-type="bibr">90</xref>, <xref rid="bib91" ref-type="bibr">91</xref>, <xref rid="bib92" ref-type="bibr">92</xref>, <xref rid="bib93" ref-type="bibr">93</xref> Moreover, in vitro susceptibility of viruses may not correlate with clinical efficacy, as in the case of interferon-alpha used for the treatment of genital herpes.<xref rid="bib94" ref-type="bibr"><sup>94</sup></xref> No improvement in symptoms score or duration of genital lesions was found irrespective of whether systemic or topical interferon-alpha was used.<xref rid="bib95" ref-type="bibr"><sup>95</sup></xref> In the case of acute RSV bronchiolitis, the efficacy of aerosolized ribavirin was also questionable.<xref rid="bib96" ref-type="bibr">96</xref>, <xref rid="bib97" ref-type="bibr">97</xref></p><p>Due to the lack of effective antiviral therapy for viral pneumonia, alternative strategies using immunomodulation were proposed as early as the 1970s.<xref rid="bib21" ref-type="bibr"><sup>21</sup></xref> This was not unexpected, since the cytotoxic T cell response may lead to immunopathological damage after an initial period of host damage mediated by virus induced cytolysis. The present literature review suggests that at least in the case of human influenza A virus and hantavirus pneumonia, steroid therapy alone may improve the outcome.<xref rid="bib20" ref-type="bibr">20</xref>, <xref rid="bib21" ref-type="bibr">21</xref>, <xref rid="bib22" ref-type="bibr">22</xref>, <xref rid="bib52" ref-type="bibr">52</xref>, <xref rid="bib53" ref-type="bibr">53</xref> In the case of VZV pneumonia, the absence of mortality in cases treated with the addition of steroid to an efficacious antiviral agent such as acyclovir seems to support such an approach.<xref rid="bib28" ref-type="bibr">28</xref>, <xref rid="bib29" ref-type="bibr">29</xref>, <xref rid="bib39" ref-type="bibr">39</xref>, <xref rid="bib40" ref-type="bibr">40</xref>, <xref rid="bib41" ref-type="bibr">41</xref> Despite some decrease in mortality in patients (47.7% vs. 63.4%), ribavirin is not considered as an effective antiviral for hantavirus.<xref rid="bib51" ref-type="bibr">51</xref>, <xref rid="bib52" ref-type="bibr">52</xref>, <xref rid="bib53" ref-type="bibr">53</xref>, <xref rid="bib54" ref-type="bibr">54</xref>, <xref rid="bib55" ref-type="bibr">55</xref> However, the use of steroids during the phase of severe ARDS of hantavirus pulmonary syndrome may be associated with reduction in mortality (13.3% vs. 63.4%).<xref rid="bib52" ref-type="bibr">52</xref>, <xref rid="bib53" ref-type="bibr">53</xref> As emphasized by a group reporting on a cluster of adenoviral pneumonia, the use of high dose steroids without an effective antiviral may actually increase mortality.<xref rid="bib47" ref-type="bibr"><sup>47</sup></xref> However the number of adenoviral pneumonia treated by steroids is too small to justify such a conclusion. Overall, the dosage and duration of steroid therapy for viral pneumonia were extremely heterogenous, future randomized clinical studies should be conducted to ascertain the dosage and duration of steroids associated with the least complication which includes secondary infection and avascular necrosis of bone.</p><p>Another difficulty in the management of viral pneumonia is the early peaking of the virus load which leaves a narrow window of opportunity for antiviral treatment.<xref rid="bib73" ref-type="bibr">73</xref>, <xref rid="bib74" ref-type="bibr">74</xref> In both human influenza A and RSV, the virus loads peaked at around 2–3 days after symptom onset in natural and experimental infections of healthy adults (<xref rid="fig1" ref-type="fig">Fig. 1</xref>).<xref rid="bib73" ref-type="bibr">73</xref>, <xref rid="bib74" ref-type="bibr">74</xref> The early control of virus load in these two infections may be explained by the brisk antibody response, possibly due to previous antigenic exposure (<xref rid="fig2" ref-type="fig">Fig. 2</xref>).<xref rid="bib73" ref-type="bibr">73</xref>, <xref rid="bib74" ref-type="bibr">74</xref> A completely different picture emerges in the case of SARS. The virus load in SARS patients peaked at around day 10 with a very large area under the curve when compared with those of human influenza A virus and RSV (<xref rid="fig1" ref-type="fig">Fig. 1</xref>). The onset of antibody response was also delayed and started to appear at around day 10. The failure of innate immunity and the relatively delayed onset of adaptive antibody response to control virus replication may be the explanations for the high mortality of this infection. Our previous studies showed that mortality is directly related to the virus load in nasopharyngeal specimens on admission and at day 10.<xref rid="bib16" ref-type="bibr">16</xref>, <xref rid="bib98" ref-type="bibr">98</xref> The mortality was also correlated with the number of RT-PCR positive specimens from different body sites including nasopharyngeal, serum, stool, or urine.<xref rid="bib98" ref-type="bibr"><sup>98</sup></xref> Therefore, an effective antiviral which could reduce the peak virus load and area under the curve is the key to the successful treatment of SARS and perhaps avian influenza A H5N1 virus, since the general population has no immunological memory towards these two viruses.</p><p>Intravenous ribavirin was empirically used as a broad-spectrum antiviral agent at the beginning of the SARS epidemic in many countries.<xref rid="bib3" ref-type="bibr">3</xref>, <xref rid="bib4" ref-type="bibr">4</xref>, <xref rid="bib5" ref-type="bibr">5</xref>, <xref rid="bib8" ref-type="bibr">8</xref>, <xref rid="bib59" ref-type="bibr">59</xref>, <xref rid="bib60" ref-type="bibr">60</xref>, <xref rid="bib61" ref-type="bibr">61</xref>, <xref rid="bib62" ref-type="bibr">62</xref>, <xref rid="bib63" ref-type="bibr">63</xref>, <xref rid="bib66" ref-type="bibr">66</xref> Ribavirin was selected as it has broad-spectrum antiviral activities possibly through the interference of cellular inosine monophosphate dehydrogenase.<xref rid="bib99" ref-type="bibr"><sup>99</sup></xref> It has been shown to be effective against mouse coronavirus in the setting of fulminant murine hepatitis.<xref rid="bib100" ref-type="bibr"><sup>100</sup></xref> Although the in vitro antiviral activity of ribavirin is weak, it has an indirect immunomodulatory activity by decreasing the release of proinflammatory cytokines from macrophages of mice. It may also switch the immune response of mice from a T-helper-2 to a T-helper-1 response,<xref rid="bib100" ref-type="bibr"><sup>100</sup></xref> which is beneficial for most intracellular infection. Subsequently in vitro susceptibility testing suggests that antiviral effect could only be achieved at a very high concentration which is difficult to achieve clinically,<xref rid="bib101" ref-type="bibr"><sup>101</sup></xref> despite the fact that ribavirin is known to be concentrated in some cell lines such as African green monkey kidney (Vero 76) and mouse 3T3 cells.<xref rid="bib102" ref-type="bibr"><sup>102</sup></xref> Moreover, the use of high dose regimens indicated for the treatment of haemorrhagic fever was associated with significant hemolysis.<xref rid="bib12" ref-type="bibr">12</xref>, <xref rid="bib72" ref-type="bibr">72</xref> Thus other options were diligently searched during the epidemic. Lopinavir/ritonavir was then used in addition to ribavirin because of a weak in vitro antiviral activity on the prototype SARS-CoV.<xref rid="bib10" ref-type="bibr"><sup>10</sup></xref> The checkerboard assay demonstrated synergisim between lopinavir and ribavirin at a low viral inoculum.<xref rid="bib10" ref-type="bibr"><sup>10</sup></xref> Other reports suggested that glycyrrhizin, interferon beta (Betaferon), interferon alpha <italic>n</italic>−1 (Wellferon), interferon alpha <italic>n</italic>−3 (Alferon), leucocytic interferon alpha, and baicalin may also have in vitro activity.<xref rid="bib101" ref-type="bibr">101</xref>, <xref rid="bib103" ref-type="bibr">103</xref>, <xref rid="bib104" ref-type="bibr">104</xref>, <xref rid="bib105" ref-type="bibr">105</xref> However, interferons were not considered by most clinicians during the epidemic because of their known proinflammatory activity, which may potentiate the inflammatory damage initiated by the viral infection, and the reported side effects of interstitial pneumonitis and bronchiolitis obliterans organizing pneumonia.<xref rid="bib106" ref-type="bibr"><sup>106</sup></xref> Subsequently pegylated recombinant interferon alpha 2b was shown to be effective as pre-exposure and perhaps very early postexposure prophylaxis in cynomolgus macaques (<italic>Macaca fascicularis</italic>) experimentally infected with SARS-CoV.<xref rid="bib107" ref-type="bibr"><sup>107</sup></xref> Though different preparations of interferons appeared to be effective in vitro, only recombinant interferon alpha and interferon alfacon-1 has been used in SARS patients.<xref rid="bib61" ref-type="bibr">61</xref>, <xref rid="bib65" ref-type="bibr">65</xref> Moreover it is still early to suggest which interferon is likely to be effective in human trial because contradictory reports on the in vitro susceptibility tests were reported for interferon beta 1a<xref rid="bib101" ref-type="bibr">101</xref>, <xref rid="bib108" ref-type="bibr">108</xref> and interferon alpha 2b.<xref rid="bib101" ref-type="bibr">101</xref>, <xref rid="bib109" ref-type="bibr">109</xref></p><p>This review has summarized the anecdotal reports on the treatment of viral pneumonia. The findings may be biased since positive results are more likely to be reported. Steroids appeared to confer some benefit in patients with ARDS due to hantavirus, human influenza virus and VZV. However, the early use of high dose steroids may be counterproductive in the absence of an effective antiviral agent. Randomized placebo controlled trials utilizing different regimens of antivirals with or without steroids should be considered for the treatment of SARS and other viral pneumonias in the future.</p></sec></body><back><ref-list><title>References</title><ref id="bib1"><label>1</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Guan</surname><given-names>Y.</given-names></name><name><surname>Zheng</surname><given-names>B.J.</given-names></name><name><surname>He</surname><given-names>Y.Q.</given-names></name></person-group><article-title>Isolation and characterization of viruses related to the SARS coronavirus from animals in southern China</article-title><source>Science</source><volume>302</volume><year>2003</year><fpage>276</fpage><lpage>278</lpage><pub-id pub-id-type="pmid">12958366</pub-id></element-citation></ref><ref id="bib2"><label>2</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Webster</surname><given-names>R.G.</given-names></name></person-group><article-title>Wet markets—a continuing source of severe acute respiratory syndrome and influenza?</article-title><source>Lancet</source><volume>363</volume><year>2004</year><fpage>234</fpage><lpage>236</lpage><pub-id pub-id-type="pmid">14738798</pub-id></element-citation></ref><ref id="bib3"><label>3</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Poutanen</surname><given-names>S.M.</given-names></name><name><surname>Low</surname><given-names>D.E.</given-names></name><name><surname>Henry</surname><given-names>B.</given-names></name></person-group><article-title>Identification of severe acute respiratory syndrome in Canada</article-title><source>N Engl J Med</source><volume>348</volume><year>2003</year><fpage>1995</fpage><lpage>2005</lpage><pub-id pub-id-type="pmid">12671061</pub-id></element-citation></ref><ref id="bib4"><label>4</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tsang</surname><given-names>K.W.</given-names></name><name><surname>Ho</surname><given-names>P.L.</given-names></name><name><surname>Ooi</surname><given-names>G.C.</given-names></name></person-group><article-title>A cluster of cases of severe acute respiratory syndrome in Hong Kong</article-title><source>N Engl J Med</source><volume>348</volume><year>2003</year><fpage>1977</fpage><lpage>1985</lpage><pub-id pub-id-type="pmid">12671062</pub-id></element-citation></ref><ref id="bib5"><label>5</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Peiris</surname><given-names>J.S.</given-names></name><name><surname>Lai</surname><given-names>S.T.</given-names></name><name><surname>Poon</surname><given-names>L.L.</given-names></name></person-group><article-title>Coronavirus as a possible cause of severe acute respiratory syndrome</article-title><source>Lancet</source><volume>361</volume><year>2003</year><fpage>1319</fpage><lpage>1325</lpage><pub-id pub-id-type="pmid">12711465</pub-id></element-citation></ref><ref id="bib6"><label>6</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yuen</surname><given-names>K.Y.</given-names></name><name><surname>Chan</surname><given-names>P.K.</given-names></name><name><surname>Peiris</surname><given-names>M.</given-names></name></person-group><article-title>Clinical features and rapid viral diagnosis of human disease associated with avian influenza A H5N1 virus</article-title><source>Lancet</source><volume>351</volume><year>1998</year><fpage>467</fpage><lpage>471</lpage><pub-id pub-id-type="pmid">9482437</pub-id></element-citation></ref><ref id="bib7"><label>7</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tran</surname><given-names>T.H.</given-names></name><name><surname>Nguyen</surname><given-names>T.L.</given-names></name><name><surname>Nguyen</surname><given-names>T.D.</given-names></name></person-group><article-title>Avian influenza A (H5N1) in 10 patients in Vietnam</article-title><source>N Engl J Med</source><volume>350</volume><year>2004</year><fpage>1179</fpage><lpage>1188</lpage><pub-id pub-id-type="pmid">14985470</pub-id></element-citation></ref><ref id="bib8"><label>8</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Peiris</surname><given-names>J.S.</given-names></name><name><surname>Chu</surname><given-names>C.M.</given-names></name><name><surname>Cheng</surname><given-names>V.C.</given-names></name></person-group><article-title>Clinical progression and virus load in a community outbreak of coronavirus-associated SARS pneumonia: a prospective study</article-title><source>Lancet</source><volume>361</volume><year>2003</year><fpage>1767</fpage><lpage>1772</lpage><pub-id pub-id-type="pmid">12781535</pub-id></element-citation></ref><ref id="bib9"><label>9</label><mixed-citation publication-type="other">World Health Organization. Summary table of SARS cases by country, 1 November 2002–7 August 2003. Available at: <ext-link ext-link-type="uri" xlink:href="http://www.who.int/csr/sars/country/en/country2003_08_15.pdf" id="interref1">http://www.who.int/csr/sars/country/en/country2003_08_15.pdf</ext-link>. Accessed March 25, 2004.</mixed-citation></ref><ref id="bib10"><label>10</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chu</surname><given-names>C.M.</given-names></name><name><surname>Cheng</surname><given-names>V.C.</given-names></name><name><surname>Hung</surname><given-names>I.F.</given-names></name></person-group><article-title>Role of lopinavir/ritonavir in the treatment of SARS: initial virological and clinical findings</article-title><source>Thorax</source><volume>59</volume><year>2004</year><fpage>252</fpage><lpage>256</lpage><pub-id pub-id-type="pmid">14985565</pub-id></element-citation></ref><ref id="bib11"><label>11</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cyranoski</surname><given-names>D.</given-names></name></person-group><article-title>Critics slam treatment for SARS as ineffective and perhaps dangerous</article-title><source>Nature</source><volume>423</volume><year>2003</year><fpage>4</fpage><pub-id pub-id-type="pmid">12721587</pub-id></element-citation></ref><ref id="bib12"><label>12</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Knowles</surname><given-names>S.R.</given-names></name><name><surname>Phillips</surname><given-names>E.J.</given-names></name><name><surname>Dresser</surname><given-names>L.</given-names></name><name><surname>Matukas</surname><given-names>L.</given-names></name></person-group><article-title>Common adverse events associated with the use of ribavirin for severe acute respiratory syndrome in Canada</article-title><source>Clin Infect Dis</source><volume>37</volume><year>2003</year><fpage>1139</fpage><lpage>1142</lpage><pub-id pub-id-type="pmid">14523782</pub-id></element-citation></ref><ref id="bib13"><label>13</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Oba</surname><given-names>Y.</given-names></name></person-group><article-title>The use of corticosteroids in SARS</article-title><source>N Engl J Med</source><volume>348</volume><year>2003</year><fpage>2034</fpage><lpage>2035</lpage><pub-id pub-id-type="pmid">12748321</pub-id></element-citation></ref><ref id="bib14"><label>14</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bernard</surname><given-names>G.R.</given-names></name></person-group><article-title>Corticosteroids: the ‘terminator’ of all untreatable serious pulmonary illness</article-title><source>Am J Respir Crit Care Med</source><volume>168</volume><year>2003</year><fpage>1409</fpage><lpage>1410</lpage><pub-id pub-id-type="pmid">14668251</pub-id></element-citation></ref><ref id="bib15"><label>15</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chan</surname><given-names>K.H.</given-names></name><name><surname>Poon</surname><given-names>L.L.</given-names></name><name><surname>Cheng</surname><given-names>V.C.</given-names></name></person-group><article-title>Detection of SARS coronavirus in patients with suspected SARS</article-title><source>Emerg Infect Dis</source><volume>10</volume><year>2004</year><fpage>294</fpage><lpage>299</lpage><pub-id pub-id-type="pmid">15030700</pub-id></element-citation></ref><ref id="bib16"><label>16</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cheng</surname><given-names>V.C.</given-names></name><name><surname>Hung</surname><given-names>I.F.</given-names></name><name><surname>Tang</surname><given-names>B.S.</given-names></name></person-group><article-title>Viral replication in the nasopharynx is associated with diarrhea in patients with severe acute respiratory syndrome</article-title><source>Clin Infect Dis</source><volume>38</volume><year>2004</year><fpage>467</fpage><lpage>475</lpage><pub-id pub-id-type="pmid">14765337</pub-id></element-citation></ref><ref id="bib17"><label>17</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Taylor</surname><given-names>G.J.</given-names></name><name><surname>Brenner</surname><given-names>W.</given-names></name><name><surname>Summer</surname><given-names>W.R.</given-names></name></person-group><article-title>Severe viral pneumonia in young adults</article-title><source>Chest</source><volume>69</volume><year>1976</year><fpage>722</fpage><lpage>728</lpage><pub-id pub-id-type="pmid">776544</pub-id></element-citation></ref><ref id="bib18"><label>18</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Winterbauer</surname><given-names>R.H.</given-names></name><name><surname>Ludwig</surname><given-names>W.R.</given-names></name><name><surname>Hammar</surname><given-names>S.P.</given-names></name></person-group><article-title>Clinical course, management, and long-term sequelae of respiratory failure due to influenza viral pneumonia</article-title><source>Johns Hopkins Med J</source><volume>141</volume><year>1977</year><fpage>148</fpage><lpage>155</lpage><pub-id pub-id-type="pmid">894855</pub-id></element-citation></ref><ref id="bib19"><label>19</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Oliveira</surname><given-names>E.C.</given-names></name><name><surname>Marik</surname><given-names>P.E.</given-names></name><name><surname>Colice</surname><given-names>G.</given-names></name></person-group><article-title>Influenza pneumonia: a descriptive study</article-title><source>Chest</source><volume>119</volume><year>2001</year><fpage>1717</fpage><lpage>1723</lpage><pub-id pub-id-type="pmid">11399696</pub-id></element-citation></ref><ref id="bib20"><label>20</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kawayama</surname><given-names>T.</given-names></name><name><surname>Fujiki</surname><given-names>R.</given-names></name><name><surname>Rikimaru</surname><given-names>T.</given-names></name><name><surname>Oizumi</surname><given-names>K.</given-names></name></person-group><article-title>Clinical study of severe influenza virus pneumonia that caused acute respiratory failure</article-title><source>Kurume Med J</source><volume>48</volume><year>2001</year><fpage>273</fpage><lpage>279</lpage><pub-id pub-id-type="pmid">11830927</pub-id></element-citation></ref><ref id="bib21"><label>21</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ferstenfeld</surname><given-names>J.E.</given-names></name><name><surname>Schlueter</surname><given-names>D.P.</given-names></name><name><surname>Rytel</surname><given-names>M.W.</given-names></name><name><surname>Molloy</surname><given-names>R.P.</given-names></name></person-group><article-title>Recognition and treatment of adult respiratory distress syndrome secondary to viral interstitial pneumonia</article-title><source>Am J Med</source><volume>58</volume><year>1975</year><fpage>709</fpage><lpage>718</lpage><pub-id pub-id-type="pmid">1173323</pub-id></element-citation></ref><ref id="bib22"><label>22</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Greaves</surname><given-names>I.A.</given-names></name><name><surname>Colebatch</surname><given-names>H.J.</given-names></name><name><surname>Torda</surname><given-names>T.A.</given-names></name></person-group><article-title>A possible role for corticosteroids in the treatment of influenzal pneumonia</article-title><source>Aust N Z J Med</source><volume>11</volume><year>1981</year><fpage>271</fpage><lpage>276</lpage><pub-id pub-id-type="pmid">6945841</pub-id></element-citation></ref><ref id="bib23"><label>23</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Doi</surname><given-names>M.</given-names></name><name><surname>Takao</surname><given-names>S.</given-names></name><name><surname>Kaneko</surname><given-names>K.</given-names></name></person-group><article-title>Two cases of severe bronchopneumonia due to influenza A (H3N2) virus: detection of influenza virus gene using reverse transcription polymerase chain reaction</article-title><source>Intern Med</source><volume>40</volume><year>2001</year><fpage>61</fpage><lpage>67</lpage><pub-id pub-id-type="pmid">11201374</pub-id></element-citation></ref><ref id="bib24"><label>24</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chan</surname><given-names>P.K.</given-names></name></person-group><article-title>Outbreak of avian influenza A (H5N1) virus infection in Hong Kong in 1997</article-title><source>Clin Infect Dis</source><volume>34</volume><issue>Suppl 2</issue><year>2002</year><fpage>S58</fpage><lpage>S64</lpage><pub-id pub-id-type="pmid">11938498</pub-id></element-citation></ref><ref id="bib25"><label>25</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Peiris</surname><given-names>J.S.</given-names></name><name><surname>Yu</surname><given-names>W.C.</given-names></name><name><surname>Leung</surname><given-names>C.W.</given-names></name></person-group><article-title>Re-emergence of fatal human influenza A subtype H5N1 disease</article-title><source>Lancet</source><volume>363</volume><year>2004</year><fpage>617</fpage><lpage>619</lpage><pub-id pub-id-type="pmid">14987888</pub-id></element-citation></ref><ref id="bib26"><label>26</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hockberger</surname><given-names>R.S.</given-names></name><name><surname>Rothstein</surname><given-names>R.J.</given-names></name></person-group><article-title>Varicella pneumonia in adults: a spectrum of disease</article-title><source>Ann Emerg Med</source><volume>15</volume><year>1986</year><fpage>931</fpage><lpage>934</lpage><pub-id pub-id-type="pmid">3740580</pub-id></element-citation></ref><ref id="bib27"><label>27</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Davidson</surname><given-names>R.N.</given-names></name><name><surname>Lynn</surname><given-names>W.</given-names></name><name><surname>Savage</surname><given-names>P.</given-names></name><name><surname>Wansbrough-Jones</surname><given-names>M.H.</given-names></name></person-group><article-title>Chickenpox pneumonia: experience with antiviral treatment</article-title><source>Thorax</source><volume>43</volume><year>1988</year><fpage>627</fpage><lpage>630</lpage><pub-id pub-id-type="pmid">3175975</pub-id></element-citation></ref><ref id="bib28"><label>28</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nilsson</surname><given-names>A.</given-names></name><name><surname>Ortqvist</surname><given-names>A.</given-names></name></person-group><article-title>Severe varicella pneumonia in adults in Stockholm County 1980–1989</article-title><source>Scand J Infect Dis</source><volume>28</volume><year>1996</year><fpage>121</fpage><lpage>123</lpage><pub-id pub-id-type="pmid">8792476</pub-id></element-citation></ref><ref id="bib29"><label>29</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mer</surname><given-names>M.</given-names></name><name><surname>Richards</surname><given-names>G.A.</given-names></name></person-group><article-title>Corticosteroids in life-threatening varicella pneumonia</article-title><source>Chest</source><volume>114</volume><year>1998</year><fpage>426</fpage><lpage>431</lpage><pub-id pub-id-type="pmid">9726725</pub-id></element-citation></ref><ref id="bib30"><label>30</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Laufenburg</surname><given-names>H.F.</given-names></name></person-group><article-title>Varicella pneumonia: a case report and review</article-title><source>Am Fam Physician</source><volume>50</volume><year>1994</year><fpage>793</fpage><lpage>796</lpage><pub-id pub-id-type="pmid">8079908</pub-id></element-citation></ref><ref id="bib31"><label>31</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Oh</surname><given-names>H.M.</given-names></name><name><surname>Chew</surname><given-names>S.K.</given-names></name></person-group><article-title>Varicella pneumonia in adults—clinical spectrum</article-title><source>Ann Acad Med Singapore</source><volume>25</volume><year>1996</year><fpage>816</fpage><lpage>819</lpage><pub-id pub-id-type="pmid">9055008</pub-id></element-citation></ref><ref id="bib32"><label>32</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>DeVaul</surname><given-names>K.A.</given-names></name><name><surname>Garner</surname><given-names>C.E.</given-names></name></person-group><article-title>Varicella-zoster virus pneumonia in the adult patient</article-title><source>J Emerg Nurs</source><volume>23</volume><year>1997</year><fpage>102</fpage><lpage>104</lpage><pub-id pub-id-type="pmid">9216278</pub-id></element-citation></ref><ref id="bib33"><label>33</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Potgieter</surname><given-names>P.D.</given-names></name><name><surname>Hammond</surname><given-names>J.M.</given-names></name></person-group><article-title>Intensive care management of varicella pneumonia</article-title><source>Respir Med</source><volume>91</volume><year>1997</year><fpage>207</fpage><lpage>212</lpage><pub-id pub-id-type="pmid">9156143</pub-id></element-citation></ref><ref id="bib34"><label>34</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Schlossberg</surname><given-names>D.</given-names></name><name><surname>Littman</surname><given-names>M.</given-names></name></person-group><article-title>Varicella pneumonia</article-title><source>Arch Intern Med</source><volume>148</volume><year>1988</year><fpage>1630</fpage><lpage>1632</lpage><pub-id pub-id-type="pmid">3382308</pub-id></element-citation></ref><ref id="bib35"><label>35</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>El-Daher</surname><given-names>N.</given-names></name><name><surname>Magnussen</surname><given-names>R.</given-names></name><name><surname>Betts</surname><given-names>R.F.</given-names></name></person-group><article-title>Varicella pneumonitis: clinical presentation and experience with acyclovir treatment in immunocompetent adults</article-title><source>Int J Infect Dis</source><volume>2</volume><year>1998</year><fpage>147</fpage><lpage>151</lpage><pub-id pub-id-type="pmid">9531661</pub-id></element-citation></ref><ref id="bib36"><label>36</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chou</surname><given-names>D.W.</given-names></name><name><surname>Lee</surname><given-names>C.H.</given-names></name><name><surname>Chen</surname><given-names>C.W.</given-names></name><name><surname>Chang</surname><given-names>H.Y.</given-names></name><name><surname>Hsiue</surname><given-names>T.R.</given-names></name></person-group><article-title>Varicella pneumonia complicated by acute respiratory distress syndrome in an adult</article-title><source>J Formos Med Assoc</source><volume>98</volume><year>1999</year><fpage>778</fpage><lpage>782</lpage><pub-id pub-id-type="pmid">10705696</pub-id></element-citation></ref><ref id="bib37"><label>37</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nee</surname><given-names>P.A.</given-names></name><name><surname>Edrich</surname><given-names>P.J.</given-names></name></person-group><article-title>Chickenpox pneumonia: case report and literature review</article-title><source>J Accid Emerg Med</source><volume>16</volume><year>1999</year><fpage>147</fpage><lpage>150</lpage><pub-id pub-id-type="pmid">10191458</pub-id></element-citation></ref><ref id="bib38"><label>38</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hepburn</surname><given-names>N.C.</given-names></name><name><surname>Carley</surname><given-names>R.H.</given-names></name></person-group><article-title>Adult respiratory distress syndrome secondary to varicella infection in a young adult</article-title><source>J R Army Med Corps</source><volume>135</volume><year>1989</year><fpage>81</fpage><lpage>83</lpage><pub-id pub-id-type="pmid">2671359</pub-id></element-citation></ref><ref id="bib39"><label>39</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lau</surname><given-names>L.G.</given-names></name></person-group><article-title>Adult varicella pneumonia that responded to combined acyclovir and steroid therapy</article-title><source>Med J Malaysia</source><volume>54</volume><year>1999</year><fpage>270</fpage><lpage>272</lpage><pub-id pub-id-type="pmid">10972042</pub-id></element-citation></ref><ref id="bib40"><label>40</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Keane</surname><given-names>J.</given-names></name><name><surname>Gochuico</surname><given-names>B.</given-names></name><name><surname>Kasznica</surname><given-names>J.M.</given-names></name><name><surname>Kornfeld</surname><given-names>H.</given-names></name></person-group><article-title>Usual interstitial pneumonitis responsive to corticosteroids following varicella pneumonia</article-title><source>Chest</source><volume>113</volume><year>1998</year><fpage>249</fpage><lpage>251</lpage><pub-id pub-id-type="pmid">9440602</pub-id></element-citation></ref><ref id="bib41"><label>41</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ahmed</surname><given-names>R.</given-names></name><name><surname>Ahmed</surname><given-names>Q.A.</given-names></name><name><surname>Adhami</surname><given-names>N.A.</given-names></name><name><surname>Memish</surname><given-names>Z.A.</given-names></name></person-group><article-title>Varicella pneumonia: another ‘steroid responsive’ pneumonia?</article-title><source>J Chemother</source><volume>14</volume><year>2002</year><fpage>220</fpage><lpage>222</lpage><pub-id pub-id-type="pmid">12017381</pub-id></element-citation></ref><ref id="bib42"><label>42</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Shirai</surname><given-names>T.</given-names></name><name><surname>Sano</surname><given-names>K.</given-names></name><name><surname>Matsuyama</surname><given-names>S.</given-names></name></person-group><article-title>Varicella pneumonia in a healthy adult presenting with severe respiratory failure</article-title><source>Intern Med</source><volume>35</volume><year>1996</year><fpage>315</fpage><lpage>318</lpage><pub-id pub-id-type="pmid">8739789</pub-id></element-citation></ref><ref id="bib43"><label>43</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tokat</surname><given-names>O.</given-names></name><name><surname>Kelebek</surname><given-names>N.</given-names></name><name><surname>Turker</surname><given-names>G.</given-names></name><name><surname>Kahveci</surname><given-names>S.F.</given-names></name><name><surname>Ozcan</surname><given-names>B.</given-names></name></person-group><article-title>Intravenous immunoglobulin in adult varicella pneumonia complicated by acute respiratory distress syndrome</article-title><source>J Int Med Res</source><volume>29</volume><year>2001</year><fpage>252</fpage><lpage>255</lpage><pub-id pub-id-type="pmid">11471863</pub-id></element-citation></ref><ref id="bib44"><label>44</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dudding</surname><given-names>B.A.</given-names></name><name><surname>Wagner</surname><given-names>S.C.</given-names></name><name><surname>Zeller</surname><given-names>J.A.</given-names></name><name><surname>Gmelich</surname><given-names>J.T.</given-names></name><name><surname>French</surname><given-names>G.R.</given-names></name><name><surname>Top</surname><given-names>F.H.</given-names><suffix>Jr</suffix></name></person-group><article-title>Fatal pneumonia associated with adenovirus type 7 in three military trainees</article-title><source>N Engl J Med</source><volume>286</volume><year>1972</year><fpage>1289</fpage><lpage>1292</lpage><pub-id pub-id-type="pmid">4337012</pub-id></element-citation></ref><ref id="bib45"><label>45</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pearson</surname><given-names>R.D.</given-names></name><name><surname>Hall</surname><given-names>W.J.</given-names></name><name><surname>Menegus</surname><given-names>M.A.</given-names></name><name><surname>Douglas</surname><given-names>R.G.</given-names><suffix>Jr.</suffix></name></person-group><article-title>Diffuse pneumonitis due to adenovirus type 21 in a civilian</article-title><source>Chest</source><volume>78</volume><year>1980</year><fpage>107</fpage><lpage>109</lpage><pub-id pub-id-type="pmid">6258868</pub-id></element-citation></ref><ref id="bib46"><label>46</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Retalis</surname><given-names>P.</given-names></name><name><surname>Strange</surname><given-names>C.</given-names></name><name><surname>Harley</surname><given-names>R.</given-names></name></person-group><article-title>The spectrum of adult adenovirus pneumonia</article-title><source>Chest</source><volume>109</volume><year>1996</year><fpage>1656</fpage><lpage>1657</lpage><pub-id pub-id-type="pmid">8769529</pub-id></element-citation></ref><ref id="bib47"><label>47</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Klinger</surname><given-names>J.R.</given-names></name><name><surname>Sanchez</surname><given-names>M.P.</given-names></name><name><surname>Curtin</surname><given-names>L.A.</given-names></name><name><surname>Durkin</surname><given-names>M.</given-names></name><name><surname>Matyas</surname><given-names>B.</given-names></name></person-group><article-title>Multiple cases of life-threatening adenovirus pneumonia in a mental health care center</article-title><source>Am J Respir Crit Care Med</source><volume>157</volume><year>1998</year><fpage>645</fpage><lpage>649</lpage><pub-id pub-id-type="pmid">9476884</pub-id></element-citation></ref><ref id="bib48"><label>48</label><mixed-citation publication-type="other">Two fatal cases of adenovirus-related illness in previously healthy young adults—Illinois, 2000. <italic>MMWR Morb Mortal Wkly Rep</italic> 2001;<bold>50</bold>:553–5.</mixed-citation></ref><ref id="bib49"><label>49</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Levin</surname><given-names>S.</given-names></name><name><surname>Dietrich</surname><given-names>J.</given-names></name><name><surname>Guillory</surname><given-names>J.</given-names></name></person-group><article-title>Fatal nonbacterial pneumonia associated with Adenovirus type 4. Occurrence in an adult</article-title><source>JAMA</source><volume>201</volume><year>1967</year><fpage>975</fpage><lpage>977</lpage><pub-id pub-id-type="pmid">4293673</pub-id></element-citation></ref><ref id="bib50"><label>50</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zarraga</surname><given-names>A.L.</given-names></name><name><surname>Kerns</surname><given-names>F.T.</given-names></name><name><surname>Kitchen</surname><given-names>L.W.</given-names></name></person-group><article-title>Adenovirus pneumonia with severe sequelae in an immunocompetent adult</article-title><source>Clin Infect Dis</source><volume>15</volume><year>1992</year><fpage>712</fpage><lpage>713</lpage><pub-id pub-id-type="pmid">1420689</pub-id></element-citation></ref><ref id="bib51"><label>51</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Levy</surname><given-names>H.</given-names></name><name><surname>Simpson</surname><given-names>S.Q.</given-names></name></person-group><article-title>Hantavirus pulmonary syndrome</article-title><source>Am J Respir Crit Care Med</source><volume>149</volume><year>1994</year><fpage>1710</fpage><lpage>1713</lpage><pub-id pub-id-type="pmid">8004332</pub-id></element-citation></ref><ref id="bib52"><label>52</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Castillo</surname><given-names>C.</given-names></name><name><surname>Naranjo</surname><given-names>J.</given-names></name><name><surname>Sepulveda</surname><given-names>A.</given-names></name><name><surname>Ossa</surname><given-names>G.</given-names></name><name><surname>Levy</surname><given-names>H.</given-names></name></person-group><article-title>Hantavirus pulmonary syndrome due to Andes virus in Temuco, Chile: clinical experience with 16 adults</article-title><source>Chest</source><volume>120</volume><year>2001</year><fpage>548</fpage><lpage>554</lpage><pub-id pub-id-type="pmid">11502657</pub-id></element-citation></ref><ref id="bib53"><label>53</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Riquelme</surname><given-names>R.</given-names></name><name><surname>Riquelme</surname><given-names>M.</given-names></name><name><surname>Torres</surname><given-names>A.</given-names></name></person-group><article-title>Hantavirus pulmonary syndrome, southern Chile</article-title><source>Emerg Infect Dis</source><volume>9</volume><year>2003</year><fpage>1438</fpage><lpage>1443</lpage><pub-id pub-id-type="pmid">14718088</pub-id></element-citation></ref><ref id="bib54"><label>54</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chapman</surname><given-names>L.E.</given-names></name><name><surname>Ellis</surname><given-names>B.A.</given-names></name><name><surname>Koster</surname><given-names>F.T.</given-names></name></person-group><article-title>Discriminators between hantavirus-infected and -uninfected persons enrolled in a trial of intravenous ribavirin for presumptive hantavirus pulmonary syndrome</article-title><source>Clin Infect Dis</source><volume>34</volume><year>2002</year><fpage>293</fpage><lpage>304</lpage><pub-id pub-id-type="pmid">11774075</pub-id></element-citation></ref><ref id="bib55"><label>55</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chapman</surname><given-names>L.E.</given-names></name><name><surname>Mertz</surname><given-names>G.J.</given-names></name><name><surname>Peters</surname><given-names>C.J.</given-names></name></person-group><article-title>Intravenous ribavirin for hantavirus pulmonary syndrome: safety and tolerance during 1 year of open-label experience. Ribavirin Study Group</article-title><source>Antivir Ther</source><volume>4</volume><year>1999</year><fpage>211</fpage><lpage>219</lpage><pub-id pub-id-type="pmid">10723500</pub-id></element-citation></ref><ref id="bib56"><label>56</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Aylward</surname><given-names>R.B.</given-names></name><name><surname>Burdge</surname><given-names>D.R.</given-names></name></person-group><article-title>Ribavirin therapy of adult respiratory syncytial virus pneumonitis</article-title><source>Arch Intern Med</source><volume>151</volume><year>1991</year><fpage>2303</fpage><lpage>2304</lpage><pub-id pub-id-type="pmid">1953237</pub-id></element-citation></ref><ref id="bib57"><label>57</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rupp</surname><given-names>M.E.</given-names></name><name><surname>Schwartz</surname><given-names>M.L.</given-names></name><name><surname>Bechard</surname><given-names>D.E.</given-names></name></person-group><article-title>Measles pneumonia. Treatment of a near-fatal case with corticosteroids and vitamin A</article-title><source>Chest</source><volume>103</volume><year>1993</year><fpage>1625</fpage><lpage>1626</lpage><pub-id pub-id-type="pmid">8486065</pub-id></element-citation></ref><ref id="bib58"><label>58</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Haller</surname><given-names>A.</given-names></name><name><surname>von Segesser</surname><given-names>L.</given-names></name><name><surname>Baumann</surname><given-names>P.C.</given-names></name><name><surname>Krause</surname><given-names>M.</given-names></name></person-group><article-title>Severe respiratory insufficiency complicating Epstein–Barr virus infection: case report and review</article-title><source>Clin Infect Dis</source><volume>21</volume><year>1995</year><fpage>206</fpage><lpage>209</lpage><pub-id pub-id-type="pmid">7578734</pub-id></element-citation></ref><ref id="bib59"><label>59</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>So</surname><given-names>L.K.</given-names></name><name><surname>Lau</surname><given-names>A.C.</given-names></name><name><surname>Yam</surname><given-names>L.Y.</given-names></name></person-group><article-title>Development of a standard treatment protocol for severe acute respiratory syndrome</article-title><source>Lancet</source><volume>361</volume><year>2003</year><fpage>1615</fpage><lpage>1617</lpage><pub-id pub-id-type="pmid">12747883</pub-id></element-citation></ref><ref id="bib60"><label>60</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Choi</surname><given-names>K.W.</given-names></name><name><surname>Chau</surname><given-names>T.N.</given-names></name><name><surname>Tsang</surname><given-names>O.</given-names></name></person-group><article-title>Outcomes and prognostic factors in 267 patients with severe acute respiratory syndrome in Hong Kong</article-title><source>Ann Intern Med</source><volume>139</volume><year>2003</year><fpage>715</fpage><lpage>723</lpage><pub-id pub-id-type="pmid">14597455</pub-id></element-citation></ref><ref id="bib61"><label>61</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhao</surname><given-names>Z.</given-names></name><name><surname>Zhang</surname><given-names>F.</given-names></name><name><surname>Xu</surname><given-names>M.</given-names></name></person-group><article-title>Description and clinical treatment of an early outbreak of severe acute respiratory syndrome (SARS) in Guangzhou, PR China</article-title><source>J Med Microbiol</source><volume>52</volume><year>2003</year><fpage>715</fpage><lpage>720</lpage><pub-id pub-id-type="pmid">12867568</pub-id></element-citation></ref><ref id="bib62"><label>62</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lee</surname><given-names>N.</given-names></name><name><surname>Hui</surname><given-names>D.</given-names></name><name><surname>Wu</surname><given-names>A.</given-names></name></person-group><article-title>A major outbreak of severe acute respiratory syndrome in Hong Kong</article-title><source>N Engl J Med</source><volume>348</volume><year>2003</year><fpage>1986</fpage><lpage>1994</lpage><pub-id pub-id-type="pmid">12682352</pub-id></element-citation></ref><ref id="bib63"><label>63</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ho</surname><given-names>J.C.</given-names></name><name><surname>Ooi</surname><given-names>G.C.</given-names></name><name><surname>Mok</surname><given-names>T.Y.</given-names></name></person-group><article-title>High-dose pulse versus nonpulse corticosteroid regimens in severe acute respiratory syndrome</article-title><source>Am J Respir Crit Care Med</source><volume>168</volume><year>2003</year><fpage>1449</fpage><lpage>1456</lpage><pub-id pub-id-type="pmid">12947028</pub-id></element-citation></ref><ref id="bib64"><label>64</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chan</surname><given-names>K.S.</given-names></name><name><surname>Lai</surname><given-names>S.T.</given-names></name><name><surname>Chu</surname><given-names>C.M.</given-names></name></person-group><article-title>Treatment of severe acute respiratory syndrome with lopinavir/ritonavir: a multicentre retrospective matched cohort study</article-title><source>Hong Kong Med J</source><volume>9</volume><year>2003</year><fpage>399</fpage><lpage>406</lpage><pub-id pub-id-type="pmid">14660806</pub-id></element-citation></ref><ref id="bib65"><label>65</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Loutfy</surname><given-names>M.R.</given-names></name><name><surname>Blatt</surname><given-names>L.M.</given-names></name><name><surname>Siminovitch</surname><given-names>K.A.</given-names></name></person-group><article-title>Interferon alfacon-1 plus corticosteroids in severe acute respiratory syndrome: a preliminary study</article-title><source>JAMA</source><volume>290</volume><year>2003</year><fpage>3222</fpage><lpage>3228</lpage><pub-id pub-id-type="pmid">14693875</pub-id></element-citation></ref><ref id="bib66"><label>66</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hsu</surname><given-names>L.Y.</given-names></name><name><surname>Lee</surname><given-names>C.C.</given-names></name><name><surname>Green</surname><given-names>J.A.</given-names></name></person-group><article-title>Severe acute respiratory syndrome (SARS) in Singapore: clinical features of index patient and initial contacts</article-title><source>Emerg Infect Dis</source><volume>9</volume><year>2003</year><fpage>713</fpage><lpage>717</lpage><pub-id pub-id-type="pmid">12781012</pub-id></element-citation></ref><ref id="bib67"><label>67</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wong</surname><given-names>V.W.</given-names></name><name><surname>Dai</surname><given-names>D.</given-names></name><name><surname>Wu</surname><given-names>A.K.</given-names></name><name><surname>Sung</surname><given-names>J.J.</given-names></name></person-group><article-title>Treatment of severe acute respiratory syndrome with convalescent plasma</article-title><source>Hong Kong Med J</source><volume>9</volume><year>2003</year><fpage>199</fpage><lpage>201</lpage><pub-id pub-id-type="pmid">12777656</pub-id></element-citation></ref><ref id="bib68"><label>68</label><mixed-citation publication-type="other">Severe acute respiratory syndrome (SARS) and coronavirus testing—United States, 2003. <italic>MMWR Morb Mortal Wkly Rep</italic> 2003;<bold>52</bold>:297–302.</mixed-citation></ref><ref id="bib69"><label>69</label><mixed-citation publication-type="other">Update: severe acute respiratory syndrome—United States, 2003. <italic>MMWR Morb Mortal Wkly Rep</italic> 2003;<bold>52</bold>:332, 334–6.</mixed-citation></ref><ref id="bib70"><label>70</label><mixed-citation publication-type="other">Update: severe acute respiratory syndrome—United States, 2003. <italic>MMWR Morb Mortal Wkly Rep</italic> 2003;<bold>52</bold>:357–60.</mixed-citation></ref><ref id="bib71"><label>71</label><mixed-citation publication-type="other">Update: severe acute respiratory syndrome—United States, June 11, 2003. <italic>MMWR Morb Mortal Wkly Rep</italic> 2003;<bold>52</bold>:550.</mixed-citation></ref><ref id="bib72"><label>72</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Booth</surname><given-names>C.M.</given-names></name><name><surname>Matukas</surname><given-names>L.M.</given-names></name><name><surname>Tomlinson</surname><given-names>G.A.</given-names></name></person-group><article-title>Clinical features and short-term outcomes of 144 patients with SARS in the greater Toronto area</article-title><source>JAMA</source><volume>289</volume><year>2003</year><fpage>2801</fpage><lpage>2809</lpage><pub-id pub-id-type="pmid">12734147</pub-id></element-citation></ref><ref id="bib73"><label>73</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dolin</surname><given-names>R.</given-names></name></person-group><article-title>Influenza: current concepts</article-title><source>Am Fam Physician</source><volume>14</volume><year>1976</year><fpage>72</fpage><lpage>77</lpage><pub-id pub-id-type="pmid">961563</pub-id></element-citation></ref><ref id="bib74"><label>74</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Falsey</surname><given-names>A.R.</given-names></name><name><surname>Formica</surname><given-names>M.A.</given-names></name><name><surname>Treanor</surname><given-names>J.J.</given-names></name><name><surname>Walsh</surname><given-names>E.E.</given-names></name></person-group><article-title>Comparison of quantitative reverse transcription-PCR to viral culture for assessment of respiratory syncytial virus shedding</article-title><source>J Clin Microbiol</source><volume>41</volume><year>2003</year><fpage>4160</fpage><lpage>4165</lpage><pub-id pub-id-type="pmid">12958241</pub-id></element-citation></ref><ref id="bib75"><label>75</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>File</surname><given-names>T.M.</given-names></name></person-group><article-title>Community-acquired pneumonia</article-title><source>Lancet</source><volume>362</volume><year>2003</year><fpage>1991</fpage><lpage>2001</lpage><pub-id pub-id-type="pmid">14683661</pub-id></element-citation></ref><ref id="bib76"><label>76</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ruiz-Gonzalez</surname><given-names>A.</given-names></name><name><surname>Falguera</surname><given-names>M.</given-names></name><name><surname>Nogues</surname><given-names>A.</given-names></name><name><surname>Rubio-Caballero</surname><given-names>M.</given-names></name></person-group><article-title>Is <italic>Streptococcus pneumoniae</italic> the leading cause of pneumonia of unknown etiology? A microbiologic study of lung aspirates in consecutive patients with community-acquired pneumonia</article-title><source>Am J Med</source><volume>106</volume><year>1999</year><fpage>385</fpage><lpage>390</lpage><pub-id pub-id-type="pmid">10225239</pub-id></element-citation></ref><ref id="bib77"><label>77</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ishida</surname><given-names>T.</given-names></name><name><surname>Hashimoto</surname><given-names>T.</given-names></name><name><surname>Arita</surname><given-names>M.</given-names></name><name><surname>Ito</surname><given-names>I.</given-names></name><name><surname>Osawa</surname><given-names>M.</given-names></name></person-group><article-title>Etiology of community-acquired pneumonia in hospitalized patients: a 3-year prospective study in Japan</article-title><source>Chest</source><volume>114</volume><year>1998</year><fpage>1588</fpage><lpage>1593</lpage><pub-id pub-id-type="pmid">9872193</pub-id></element-citation></ref><ref id="bib78"><label>78</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Robbins</surname><given-names>G.K.</given-names></name><name><surname>De Gruttola</surname><given-names>V.</given-names></name><name><surname>Shafer</surname><given-names>R.W.</given-names></name></person-group><article-title>Comparison of sequential three-drug regimens as initial therapy for HIV-1 infection</article-title><source>N Engl J Med</source><volume>349</volume><year>2003</year><fpage>2293</fpage><lpage>2303</lpage><pub-id pub-id-type="pmid">14668455</pub-id></element-citation></ref><ref id="bib79"><label>79</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Shafer</surname><given-names>R.W.</given-names></name><name><surname>Smeaton</surname><given-names>L.M.</given-names></name><name><surname>Robbins</surname><given-names>G.K.</given-names></name></person-group><article-title>Comparison of four-drug regimens and pairs of sequential three-drug regimens as initial therapy for HIV-1 infection</article-title><source>N Engl J Med</source><volume>349</volume><year>2003</year><fpage>2304</fpage><lpage>2315</lpage><pub-id pub-id-type="pmid">14668456</pub-id></element-citation></ref><ref id="bib80"><label>80</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jaeckel</surname><given-names>E.</given-names></name><name><surname>Cornberg</surname><given-names>M.</given-names></name><name><surname>Wedemeyer</surname><given-names>H.</given-names></name></person-group><article-title>Treatment of acute hepatitis C with interferon alfa-2b</article-title><source>N Engl J Med</source><volume>345</volume><year>2001</year><fpage>1452</fpage><lpage>1457</lpage><pub-id pub-id-type="pmid">11794193</pub-id></element-citation></ref><ref id="bib81"><label>81</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fried</surname><given-names>M.W.</given-names></name><name><surname>Shiffman</surname><given-names>M.L.</given-names></name><name><surname>Reddy</surname><given-names>K.R.</given-names></name></person-group><article-title>Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection</article-title><source>N Engl J Med</source><volume>347</volume><year>2002</year><fpage>975</fpage><lpage>982</lpage><pub-id pub-id-type="pmid">12324553</pub-id></element-citation></ref><ref id="bib82"><label>82</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Manns</surname><given-names>M.P.</given-names></name><name><surname>McHutchison</surname><given-names>J.G.</given-names></name><name><surname>Gordon</surname><given-names>S.C.</given-names></name></person-group><article-title>Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial</article-title><source>Lancet</source><volume>358</volume><year>2001</year><fpage>958</fpage><lpage>965</lpage><pub-id pub-id-type="pmid">11583749</pub-id></element-citation></ref><ref id="bib83"><label>83</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lai</surname><given-names>C.L.</given-names></name><name><surname>Chien</surname><given-names>R.N.</given-names></name><name><surname>Leung</surname><given-names>N.W.</given-names></name></person-group><article-title>A one-year trial of lamivudine for chronic hepatitis B. Asia Hepatitis Lamivudine Study Group</article-title><source>N Engl J Med</source><volume>339</volume><year>1998</year><fpage>61</fpage><lpage>68</lpage><pub-id pub-id-type="pmid">9654535</pub-id></element-citation></ref><ref id="bib84"><label>84</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dienstag</surname><given-names>J.L.</given-names></name><name><surname>Schiff</surname><given-names>E.R.</given-names></name><name><surname>Wright</surname><given-names>T.L.</given-names></name></person-group><article-title>Lamivudine as initial treatment for chronic hepatitis B in the United States</article-title><source>N Engl J Med</source><volume>341</volume><year>1999</year><fpage>1256</fpage><lpage>1263</lpage><pub-id pub-id-type="pmid">10528035</pub-id></element-citation></ref><ref id="bib85"><label>85</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Leone</surname><given-names>P.A.</given-names></name><name><surname>Trottier</surname><given-names>S.</given-names></name><name><surname>Miller</surname><given-names>J.M.</given-names></name></person-group><article-title>Valacyclovir for episodic treatment of genital herpes: a shorter 3-day treatment course compared with 5-day treatment</article-title><source>Clin Infect Dis</source><volume>34</volume><year>2002</year><fpage>958</fpage><lpage>962</lpage><pub-id pub-id-type="pmid">11880962</pub-id></element-citation></ref><ref id="bib86"><label>86</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Corey</surname><given-names>L.</given-names></name><name><surname>Wald</surname><given-names>A.</given-names></name><name><surname>Patel</surname><given-names>R.</given-names></name></person-group><article-title>Once-daily valacyclovir to reduce the risk of transmission of genital herpes</article-title><source>N Engl J Med</source><volume>350</volume><year>2004</year><fpage>11</fpage><lpage>20</lpage><pub-id pub-id-type="pmid">14702423</pub-id></element-citation></ref><ref id="bib87"><label>87</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Balfour</surname><given-names>H.H.</given-names><suffix>Jr</suffix></name><name><surname>Rotbart</surname><given-names>H.A.</given-names></name><name><surname>Feldman</surname><given-names>S.</given-names></name></person-group><article-title>Acyclovir treatment of varicella in otherwise healthy adolescents. The Collaborative Acyclovir Varicella Study Group</article-title><source>J Pediatr</source><volume>120</volume><year>1992</year><fpage>627</fpage><lpage>633</lpage><pub-id pub-id-type="pmid">1313098</pub-id></element-citation></ref><ref id="bib88"><label>88</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wallace</surname><given-names>M.R.</given-names></name><name><surname>Bowler</surname><given-names>W.A.</given-names></name><name><surname>Murray</surname><given-names>N.B.</given-names></name><name><surname>Brodine</surname><given-names>S.K.</given-names></name><name><surname>Oldfield</surname><given-names>E.C.</given-names><suffix>3rd</suffix></name></person-group><article-title>Treatment of adult varicella with oral acyclovir. A randomized, placebo-controlled trial</article-title><source>Ann Intern Med</source><volume>117</volume><year>1992</year><fpage>358</fpage><lpage>363</lpage><pub-id pub-id-type="pmid">1323943</pub-id></element-citation></ref><ref id="bib89"><label>89</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Salmon-Ceron</surname><given-names>D.</given-names></name><name><surname>Fillet</surname><given-names>A.M.</given-names></name><name><surname>Aboulker</surname><given-names>J.P.</given-names></name></person-group><article-title>Effect of a 14-day course of foscarnet on cytomegalovirus (CMV) blood markers in a randomized study of human immunodeficiency virus-infected patients with persistent CMV viremia. Agence National de Recherche du SIDA 023 Study Group</article-title><source>Clin Infect Dis</source><volume>28</volume><year>1999</year><fpage>901</fpage><lpage>905</lpage><pub-id pub-id-type="pmid">10825058</pub-id></element-citation></ref><ref id="bib90"><label>90</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Martin</surname><given-names>D.F.</given-names></name><name><surname>Sierra-Madero</surname><given-names>J.</given-names></name><name><surname>Walmsley</surname><given-names>S.</given-names></name></person-group><article-title>A controlled trial of valganciclovir as induction therapy for cytomegalovirus retinitis</article-title><source>N Engl J Med</source><volume>346</volume><year>2002</year><fpage>1119</fpage><lpage>1126</lpage><pub-id pub-id-type="pmid">11948271</pub-id></element-citation></ref><ref id="bib91"><label>91</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nicholson</surname><given-names>K.G.</given-names></name><name><surname>Aoki</surname><given-names>F.Y.</given-names></name><name><surname>Osterhaus</surname><given-names>A.D.</given-names></name></person-group><article-title>Efficacy and safety of oseltamivir in treatment of acute influenza: a randomised controlled trial. Neuraminidase Inhibitor Flu Treatment Investigator Group</article-title><source>Lancet</source><volume>355</volume><year>2000</year><fpage>1845</fpage><lpage>1850</lpage><pub-id pub-id-type="pmid">10866439</pub-id></element-citation></ref><ref id="bib92"><label>92</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Treanor</surname><given-names>J.J.</given-names></name><name><surname>Hayden</surname><given-names>F.G.</given-names></name><name><surname>Vrooman</surname><given-names>P.S.</given-names></name></person-group><article-title>Efficacy and safety of the oral neuraminidase inhibitor oseltamivir in treating acute influenza: a randomized controlled trial. US Oral Neuraminidase Study Group</article-title><source>JAMA</source><volume>283</volume><year>2000</year><fpage>1016</fpage><lpage>1024</lpage><pub-id pub-id-type="pmid">10697061</pub-id></element-citation></ref><ref id="bib93"><label>93</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hedrick</surname><given-names>J.A.</given-names></name><name><surname>Barzilai</surname><given-names>A.</given-names></name><name><surname>Behre</surname><given-names>U.</given-names></name></person-group><article-title>Zanamivir for treatment of symptomatic influenza A and B infection in children five to twelve years of age: a randomized controlled trial</article-title><source>Pediatr Infect Dis J</source><volume>19</volume><year>2000</year><fpage>410</fpage><lpage>417</lpage><pub-id pub-id-type="pmid">10819336</pub-id></element-citation></ref><ref id="bib94"><label>94</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Eron</surname><given-names>L.J.</given-names></name><name><surname>Toy</surname><given-names>C.</given-names></name><name><surname>Salsitz</surname><given-names>B.</given-names></name><name><surname>Scheer</surname><given-names>R.R.</given-names></name><name><surname>Wood</surname><given-names>D.L.</given-names></name><name><surname>Nadler</surname><given-names>P.I.</given-names></name></person-group><article-title>Therapy of genital herpes with topically applied interferon</article-title><source>Antimicrob Agents Chemother</source><volume>31</volume><year>1987</year><fpage>1137</fpage><lpage>1139</lpage><pub-id pub-id-type="pmid">3310870</pub-id></element-citation></ref><ref id="bib95"><label>95</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Levin</surname><given-names>M.J.</given-names></name><name><surname>Judson</surname><given-names>F.N.</given-names></name><name><surname>Eron</surname><given-names>L.</given-names></name></person-group><article-title>Comparison of intramuscular recombinant alpha interferon (rIFN-2A) with topical acyclovir for the treatment of first-episode herpes genitalis and prevention of recurrences</article-title><source>Antimicrob Agents Chemother</source><volume>33</volume><year>1989</year><fpage>649</fpage><lpage>652</lpage><pub-id pub-id-type="pmid">2751279</pub-id></element-citation></ref><ref id="bib96"><label>96</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Moler</surname><given-names>F.W.</given-names></name><name><surname>Steinhart</surname><given-names>C.M.</given-names></name><name><surname>Ohmit</surname><given-names>S.E.</given-names></name><name><surname>Stidham</surname><given-names>G.L.</given-names></name></person-group><article-title>Effectiveness of ribavirin in otherwise well infants with respiratory syncytial virus-associated respiratory failure. Pediatric Critical Study Group</article-title><source>J Pediatr</source><volume>128</volume><year>1996</year><fpage>422</fpage><lpage>428</lpage><pub-id pub-id-type="pmid">8774517</pub-id></element-citation></ref><ref id="bib97"><label>97</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Guerguerian</surname><given-names>A.M.</given-names></name><name><surname>Gauthier</surname><given-names>M.</given-names></name><name><surname>Lebel</surname><given-names>M.H.</given-names></name><name><surname>Farrell</surname><given-names>C.A.</given-names></name><name><surname>Lacroix</surname><given-names>J.</given-names></name></person-group><article-title>Ribavirin in ventilated respiratory syncytial virus bronchiolitis. A randomized, placebo-controlled trial</article-title><source>Am J Respir Crit Care Med</source><volume>160</volume><year>1999</year><fpage>829</fpage><lpage>834</lpage><pub-id pub-id-type="pmid">10471604</pub-id></element-citation></ref><ref id="bib98"><label>98</label><mixed-citation publication-type="other">Hung IF, Cheng VC, Wu AK, et al. Viral loads in clinical specimens and SARS manifestations. <italic>Emerg Infect Dis</italic> 2004 in press.</mixed-citation></ref><ref id="bib99"><label>99</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Koren</surname><given-names>G.</given-names></name><name><surname>King</surname><given-names>S.</given-names></name><name><surname>Knowles</surname><given-names>S.</given-names></name><name><surname>Phillips</surname><given-names>E.</given-names></name></person-group><article-title>Ribavirin in the treatment of SARS: a new trick for an old drug?</article-title><source>CMAJ</source><volume>168</volume><year>2003</year><fpage>1289</fpage><lpage>1292</lpage><pub-id pub-id-type="pmid">12743076</pub-id></element-citation></ref><ref id="bib100"><label>100</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ning</surname><given-names>Q.</given-names></name><name><surname>Brown</surname><given-names>D.</given-names></name><name><surname>Parodo</surname><given-names>J.</given-names></name></person-group><article-title>Ribavirin inhibits viral-induced macrophage production of TNF, IL-1, the procoagulant fgl2 prothrombinase and preserves Th1 cytokine production but inhibits Th2 cytokine response</article-title><source>J Immunol</source><volume>160</volume><year>1998</year><fpage>3487</fpage><lpage>3493</lpage><pub-id pub-id-type="pmid">9531310</pub-id></element-citation></ref><ref id="bib101"><label>101</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tan</surname><given-names>E.L.</given-names></name><name><surname>Ooi</surname><given-names>E.E.</given-names></name><name><surname>Lin</surname><given-names>C.Y.</given-names></name></person-group><article-title>Inhibition of SARS coronavirus infection in vitro with clinically approved antiviral drugs</article-title><source>Emerg Infect Dis</source><volume>10</volume><year>2004</year><fpage>581</fpage><lpage>586</lpage><pub-id pub-id-type="pmid">15200845</pub-id></element-citation></ref><ref id="bib102"><label>102</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Smee</surname><given-names>D.F.</given-names></name><name><surname>Bray</surname><given-names>M.</given-names></name><name><surname>Huggins</surname><given-names>J.W.</given-names></name></person-group><article-title>Antiviral activity and mode of action studies of ribavirin and mycophenolic acid against orthopoxviruses in vitro</article-title><source>Antivir Chem Chemother</source><volume>12</volume><year>2001</year><fpage>327</fpage><lpage>335</lpage><pub-id pub-id-type="pmid">12018677</pub-id></element-citation></ref><ref id="bib103"><label>103</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cinatl</surname><given-names>J.</given-names></name><name><surname>Morgenstern</surname><given-names>B.</given-names></name><name><surname>Bauer</surname><given-names>G.</given-names></name><name><surname>Chandra</surname><given-names>P.</given-names></name><name><surname>Rabenau</surname><given-names>H.</given-names></name><name><surname>Doerr</surname><given-names>H.W.</given-names></name></person-group><article-title>Glycyrrhizin, an active component of liquorice roots, and replication of SARS-associated coronavirus</article-title><source>Lancet</source><volume>361</volume><year>2003</year><fpage>2045</fpage><lpage>2046</lpage><pub-id pub-id-type="pmid">12814717</pub-id></element-citation></ref><ref id="bib104"><label>104</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cinatl</surname><given-names>J.</given-names></name><name><surname>Morgenstern</surname><given-names>B.</given-names></name><name><surname>Bauer</surname><given-names>G.</given-names></name><name><surname>Chandra</surname><given-names>P.</given-names></name><name><surname>Rabenau</surname><given-names>H.</given-names></name><name><surname>Doerr</surname><given-names>H.W.</given-names></name></person-group><article-title>Treatment of SARS with human interferons</article-title><source>Lancet</source><volume>362</volume><year>2003</year><fpage>293</fpage><lpage>294</lpage><pub-id pub-id-type="pmid">12892961</pub-id></element-citation></ref><ref id="bib105"><label>105</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chen</surname><given-names>F.</given-names></name><name><surname>Chan</surname><given-names>K.H.</given-names></name><name><surname>Jiang</surname><given-names>Y.</given-names></name></person-group><article-title>In vitro susceptibility of ten clinical isolates of SARS coronavirus to selected antiviral compounds</article-title><source>J Clin Virol</source><volume>31</volume><year>2004</year><fpage>69</fpage><lpage>75</lpage><pub-id pub-id-type="pmid">15288617</pub-id></element-citation></ref><ref id="bib106"><label>106</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kumar</surname><given-names>K.S.</given-names></name><name><surname>Russo</surname><given-names>M.W.</given-names></name><name><surname>Borczuk</surname><given-names>A.C.</given-names></name></person-group><article-title>Significant pulmonary toxicity associated with interferon and ribavirin therapy for hepatitis C</article-title><source>Am J Gastroenterol</source><volume>97</volume><year>2002</year><fpage>2432</fpage><lpage>2440</lpage><pub-id pub-id-type="pmid">12358269</pub-id></element-citation></ref><ref id="bib107"><label>107</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Haagmans</surname><given-names>B.L.</given-names></name><name><surname>Kuiken</surname><given-names>T.</given-names></name><name><surname>Martina</surname><given-names>B.E.</given-names></name></person-group><article-title>Pegylated interferon-alpha protects type 1 pneumocytes against SARS coronavirus infection in macaques</article-title><source>Nat Med</source><volume>10</volume><year>2004</year><fpage>290</fpage><lpage>293</lpage><pub-id pub-id-type="pmid">14981511</pub-id></element-citation></ref><ref id="bib108"><label>108</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hensley</surname><given-names>L.E.</given-names></name><name><surname>Fritz</surname><given-names>L.E.</given-names></name><name><surname>Jahrling</surname><given-names>P.B.</given-names></name><name><surname>Karp</surname><given-names>C.L.</given-names></name><name><surname>Huggins</surname><given-names>J.W.</given-names></name><name><surname>Geisbert</surname><given-names>T.W.</given-names></name></person-group><article-title>Interferon-beta 1a and SARS coronavirus replication</article-title><source>Emerg Infect Dis</source><volume>10</volume><year>2004</year><fpage>317</fpage><lpage>319</lpage><pub-id pub-id-type="pmid">15030704</pub-id></element-citation></ref><ref id="bib109"><label>109</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Stroher</surname><given-names>U.</given-names></name><name><surname>DiCaro</surname><given-names>A.</given-names></name><name><surname>Li</surname><given-names>Y.</given-names></name></person-group><article-title>Severe acute respiratory syndrome-related coronavirus is inhibited by interferon-alpha</article-title><source>J Infect Dis</source><volume>189</volume><year>2004</year><fpage>1164</fpage><lpage>1167</lpage><pub-id pub-id-type="pmid">15031783</pub-id></element-citation></ref></ref-list><ack><title>Acknowledgements</title><p>We acknowledge research funding from the Vice-Chancellor SARS Research Fund, Suen Chi Sun Charitable Foundation SARS Research Fund, The University of Hong Kong. We are most grateful to Dr Rodney Lee for critical review of the manuscript.</p></ack></back></pmc></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Sante/explor/SrasV1/Data/Pmc/Corpus
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 001188 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Pmc/Corpus/biblio.hfd -nk 001188 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Sante
|area= SrasV1
|flux= Pmc
|étape= Corpus
|type= RBID
|clé= PMC:7112637
|texte= Medical treatment of viral pneumonia including SARS in immunocompetent adult
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/Pmc/Corpus/RBID.i -Sk "pubmed:15474623" \
| HfdSelect -Kh $EXPLOR_AREA/Data/Pmc/Corpus/biblio.hfd \
| NlmPubMed2Wicri -a SrasV1
| This area was generated with Dilib version V0.6.33. |  |